carbamates has been researched along with proline in 345 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 10 (2.90) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 9 (2.61) | 29.6817 |
| 2010's | 286 (82.90) | 24.3611 |
| 2020's | 40 (11.59) | 2.80 |
| Authors | Studies |
|---|---|
| McClure, WO; Paulson, JC | 1 |
| Drillien, R; Lacroute, F | 1 |
| Cybis, J; Piotrowska, M; Weglenski, P | 1 |
| Frimpter, GW | 1 |
| De Nollin, S; Van den Bossche, H | 1 |
| Kleinkauf, H; Lipmann, F; Roskoski, R | 1 |
| Dietz, RW; Flipse, RJ | 1 |
| Barany, G | 1 |
| Cizmárik, J; Svec, J; Svec, P | 1 |
| Correia, CR; Costenaro, ER; Garcia, AL; Severino, EA | 1 |
| AMSTEY, M; BROWN, O; MCCARTY, KS; WOODSON, B | 1 |
| Bailey, MD; Bolger, G; Brochu, C; Faucher, AM; Ferland, JM; Garneau, M; Ghiro, E; Gorys, V; Grand-Maître, C; Halmos, T; Lamarre, D; Lapeyre-Paquette, N; Liard, F; Llinàs-Brunet, M; Poirier, M; Rhéaume, M; Tsantrizos, YS | 1 |
| Aebi, JD; Berger, Y; Blum-Kaelin, D; Dehmlow, H; Juillerat-Jeanneret, L; Kitas, EA; Löffler, BM | 1 |
| Bes, M; Cubero, M; Esteban, JI; Esteban, R; Guardia, J; Otero, T; Quer, J; Sauleda, S | 1 |
| Gotoh, H; Hayashi, Y; Ishikawa, H; Masui, R | 1 |
| Gonzàlez-Candelas, F; López-Labrador, FX; Moya, A | 1 |
| Antonov, D; Ayesa, S; Classon, B; de Kock, H; Delouvroy, F; Edlund, M; Eneroth, A; Hu, L; Ivanov, V; Johansson, PO; Kahnberg, P; Kindermans, N; Lenz, O; Lin, TI; Lindström, S; McGowan, D; Nilsson, M; Raboisson, P; Rosenquist, A; Samuelsson, B; Simmen, K; Surleraux, D; Tahri, A; Van de Vreken, W; Van Dooren, M; Vendeville, S; Vrang, L; Wigerinck, P; Wikstrom, K | 1 |
| Allen, TM; Berical, A; Berlin, AM; Bihl, F; Birch, C; Birren, BW; Carlson, J; Cerny, A; Chung, RT; Daar, ES; Donfield, SM; Edlin, BR; Fleckenstein, JF; Galagan, JE; Gomperts, ED; Heckerman, D; Henn, MR; Jacobson, IM; Kim, AY; Kleyman, M; Kodira, C; Koehrsen, M; Kuntzen, T; Lake-Bakaar, GV; Lauer, GM; Ledlie, T; Lee, B; Lennon, N; Liu, Z; Madey, MA; Marion, T; McMahon, CM; Nusbaum, C; Park, VM; Reyor, LL; Roberts, AD; Rosen, HR; Schneidewind, A; Schulze Zur Wiesch, J; Spengler, U; Talal, AH; Timm, J; Walker, BD; Xing, Y; Young, SK | 1 |
| Ciaramella, G; Corbau, R; Flores, MV; Strawbridge, J | 1 |
| Deshpande, M; Huang, M; Miller, MD; Mo, H; Murray, B; Qi, X; Rhodes, G; Sun, SC; Wang, K; Wang, Y; Yang, C | 1 |
| Alberts, J; Cantone, JL; Gao, M; Huang, XS; Leet, JE; Lemm, JA; Martin, SW; Meanwell, NA; Nower, PT; O'Boyle, DR; Romine, JL; Schroeder, DR; Serrano-Wu, MH; Snyder, LB; Sun, JH | 1 |
| Ashtari, M; Cann, NM | 1 |
| Belavic, JM | 1 |
| Leis, HJ; Windischhofer, W | 1 |
| Belema, M; Gao, M; Goodrich, J; Kakarla, R; Knipe, JO; Lemm, JA; Liu, M; Lopez, OD; Meanwell, NA; Nguyen, VN; Nower, PT; O'Boyle, D; Qiu, Y; Romine, JL; Serrano-Wu, MH; Snyder, LB; St Laurent, DR; Sun, JH; Valera, L; Yang, F; Yang, X | 1 |
| Belema, M; Fridell, RA; Gao, M; Good, AC; Goodrich, JT; Lemm, JA; Liu, M; Lopez, OD; Meanwell, NA; Nguyen, VN; Nower, PT; O'Boyle, DR; Qiu, Y; Ripka, AS; Serrano-Wu, MH; Snyder, LB; St Laurent, DR; Sun, JH; Valera, L; Yang, F | 1 |
| Pawlotsky, JM | 1 |
| Ban, Y; Liu, H; Xue, W; Yao, X | 1 |
| Bukh, J; Gottwein, JM; Humes, D; Jensen, SB; Li, YP; Ramirez, S | 1 |
| Dieterich, DT; Martel-Laferrière, V | 1 |
| Asselah, T; Halfon, P; Marcellin, P; Schinazi, R | 1 |
| Ford, N; Fortunak, J; Hill, A; Khoo, S; Simmons, B | 1 |
| Beno, DW; Campbell, A; Caspi, DD; Collins, C; DeGoey, DA; Donner, P; Dumas, E; Gao, Y; Hutchins, C; Kati, WM; Keddy, R; Koev, G; Krishnan, P; Krueger, AC; Liu, D; Maring, CJ; Matulenko, M; Mistry, N; Molla, A; Mondal, R; Motter, CE; Nelson, L; Patel, S; Pilot-Matias, T; Pratt, J; Randolph, JT; Reisch, TJ; Tufano, M; Wagner, R; Williams, L | 1 |
| Bernstein, B; Cohen, DE; Everson, GT; Foster, GR; Khatri, A; Kowdley, KV; Kwo, P; Larsen, L; Lawitz, E; Liossis, G; Nelson, DR; Pilot-Matias, T; Podsadecki, T; Poordad, F; Sulkowski, MS; Xie, W; Zeuzem, S | 1 |
| Anwar, MI; Danielson, UH; Ehrenberg, AE; Gustafsson, SS; Schmuck, B; Stenberg, G | 1 |
| Akberdin, IR; Clausznitzer, D; Demenkov, PS; Gursky, VV; Ivanisenko, NV; Ivanisenko, VA; Kaderali, L; Kolchanov, NA; Kozlov, KN; Likhoshvai, VA; Mishchenko, EL; Samsonov, AM; Samsonova, MG; Todorov, DI | 1 |
| Baykal, T; Bernstein, B; Bourlière, M; DaSilva-Tillmann, B; Desmond, P; Di Bisceglie, AM; Hassanein, T; Jacobson, IM; Jensen, DM; Larsen, L; Marinho, RT; Pilot-Matias, T; Podsadecki, T; Poordad, F; Sulkowski, MS; Tam, E; Varunok, P; Wedemeyer, H; Xiong, J; Zeuzem, S | 1 |
| Aguilar, H; Bernstein, B; Coakley, E; Crawford, D; DaSilva-Tillmann, B; Feld, JJ; Kowdley, KV; Larsen, L; Nelson, DR; Pilot-Matias, T; Podsadecki, T; Sigal, S; Weiland, O; Xiong, J | 1 |
| Agarwal, K; Berg, T; Bernstein, B; Campbell, AL; Collins, CA; Da Silva-Tillmann, B; Forns, X; Hezode, C; Kowdley, KV; Lovell, SS; Podsadecki, T; Poordad, F; Shiffman, ML; Trinh, R; Wedemeyer, H; Yoshida, EM; Zeuzem, S | 1 |
| Bacon, BR; Baruch, Y; Bruno, S; Caro, L; Cooreman, MP; Dutko, FJ; Fandozzi, C; Gilbert, CL; Gress, J; Howe, AY; Hwang, P; Manns, MP; Marcellin, P; Mobashery, N; Robertson, MN; Shaw, PM; Shibolet, O; Vierling, JM; Wahl, J | 1 |
| Pavri, TM; Reddy, KR; Sinese, L; Wirjosemito, A | 1 |
| Ghany, MG; Liang, TJ | 1 |
| Baruch, Y; Bernstein, D; Bhandari, BR; Box, TD; Caruntu, FA; Chulanov, V; Cohen, D; Cooper, C; Enayati, P; Ferenci, P; Gervain, J; Green, S; Hassanein, T; Janczewska, E; King, M; Lalezari, J; Luo, Y; Marinho, RT; Moreno, C; Nyberg, A; Planas, R; Podsadecki, T; Reddy, KR; Rizzardini, G; Sepe, T; Tam, E; Tsai, N; Xie, W; Younes, Z | 1 |
| Andreone, P; Bernstein, B; Colombo, MG; Enejosa, JV; Ferenci, P; Horsmans, Y; Hu, YB; Koksal, I; Maieron, A; Müllhaupt, B; Podsadecki, T; Reesink, HW; Rodrigues, L; Weiland, O | 1 |
| Barth, H; Baumert, TF; Bukh, J; Doffoël, M; Fofana, I; Habersetzer, F; Heydmann, L; Patel, AH; Soulier, E; Xiao, F; Zeisel, MB | 1 |
| Borgia, G; Buonomo, AR; Gentile, I; Zappulo, E | 1 |
| Bachovchin, DA; Bachovchin, WW; DiMare, M; Golub, TR; Healey, SE; Kiritsy, CP; Koblan, LW; Lai, JH; Li, Y; Liu, Y; Munford, RS; Poplawski, SE; Sanford, DG; Shu, Y; Woznica, I; Wu, W; Zhao, P | 1 |
| Borgia, G; Buonomo, AR; Gentile, I | 1 |
| Badri, P; Bennett, M; Campbell, A; Hu, Y; Kapoor, M; Lawitz, E; Pilot-Matias, T; Poordad, F; Rodrigues, L; Rodriguez-Torres, M; Sullivan, G; Vilchez, RA | 1 |
| Stirnimann, G | 1 |
| Agarwal, K; Cohen, D; Podsadecki, T; Poordad, F; Xie, W; Younes, Z | 1 |
| Badri, P; Brown, R; Burton, JR; Coakley, E; Forns, X; Gordon, F; Kwo, PY; Levitsky, J; Mantry, PS; Pilot-Matias, T; Setze, C; Te, HS; Terrault, NA; Vargas, HE; Vilchez, RA; Xie, W | 1 |
| Firpi, RJ; Hilgenfeldt, E | 1 |
| Cornberg, M; Höner zu Siederdissen, C | 1 |
| Beyer, J; Campbell, A; Collins, C; DeGoey, D; Kati, W; Koev, G; Krishnan, P; Mistry, N; Molla, A; Pilot-Matias, T; Reisch, T; Setze, C; Williams, L; Xie, W | 1 |
| Andreone, P; Gamal, N; Vitale, G | 1 |
| Badri, P; Chayama, K; Kumada, H; Kurosaki, M; Notsumata, K; Pilot-Matias, T; Rodrigues, L; Sato, K; Setze, C; Vilchez, RA | 1 |
| Awni, WM; Badri, PS; Coakley, EP; Dutta, S; Hu, B; Khatri, A; Menon, RM; Podsadecki, TJ; Polepally, AR; Wang, H; Wang, T; Zha, J | 1 |
| Gutierrez, J; Martin, P; Trivella, JP | 1 |
| Gale, SE; Klibanov, OM; Santevecchi, B | 1 |
| Awni, W; Badri, P; Bernstein, B; Coakley, E; Cohen, D; Ding, B; Dutta, S; Menon, R; Podsadecki, T | 1 |
| Kowdley, KV; Minaei, AA | 1 |
| Coilly, A; Duclos-Vallée, JC; Roche, B; Samuel, D | 1 |
| Asselah, T; Berenguer, M; Fleischer-Stepniewska, K; Hall, C; Hassanein, T; Hézode, C; Marcellin, P; Mobashery, N; Pilot-Matias, T; Pol, S; Reddy, KR; Redman, R; Schnell, G; Vilchez, RA | 1 |
| Aguilar, H; Cohen, DE; Felizarta, F; Galen, E; King, M; Kowdley, KV; Lalezari, J; McGovern, B; Polepally, AR; Rustgi, V; Sullivan, JG; Varunok, P | 1 |
| Beinhardt, S; Ferenci, P; Hofer, H; Peck-Radosavljevic, M | 1 |
| Halász, T; Horváth, G; Hunyady, B; Makara, M | 1 |
| Deeks, ED | 1 |
| Awni, WM; Bernstein, BM; Ding, B; Dutta, S; Khatri, A; Lawitz, EJ; Marbury, TC; Menon, RM; Mullally, VM; Podsadecki, TJ | 1 |
| Kmietowicz, Z | 1 |
| Andreone, P; Gamal, N | 1 |
| Beyer, J; Cohen, D; Collins, C; Irvin, M; Krishnan, P; Larsen, L; Pilot-Matias, T; Podsadecki, T; Reisch, T; Schnell, G; Tripathi, R; Xie, W | 1 |
| Burroughs, M; Chayama, K; Ikeda, K; Karino, Y; Kioka, K; Kumada, H; Matsuzaki, Y; Patwardhan, M; Pilot-Matias, T; Redman, R; Rodrigues, L; Sato, K; Setze, C; Suzuki, F; Toyoda, H; Vilchez, RA | 1 |
| Bailly, F; Pradat, P; Virlogeux, V; Zoulim, F | 1 |
| Akarca, US; Hall, C; Hézode, C; Lawitz, E; Makara, M; Mobashery, N; Morillas, RM; Pilot-Matias, T; Preotescu, LL; Redman, R; Thuluvath, PJ; Varunok, P; Vilchez, RA | 1 |
| Recker, K | 1 |
| Berenguer, M; Everson, G; Ferenci, P; Forns, X; Fried, MW; Lopez-Talavera, JC; Lovell, S; Pedrosa, M; Poordad, F; Shiffman, ML; Trinh, R; Wedemeyer, H | 1 |
| Birch, C; Clausen, MR; Gaardbo, JC; Gerstoft, J; Hartling, HJ; Hove, M; Nielsen, SD; Trøseid, M; Ullum, H | 1 |
| Beyer, J; Collins, C; Dekhtyar, T; Hall, C; Krishnan, P; Lu, L; Pilot-Matias, T; Reisch, T; Schnell, G; Tripathi, R; Vilchez, RA | 1 |
| Buti, M; Esteban, R; Riveiro-Barciela, M | 1 |
| Arama, V; Campbell, A; Caruntu, FA; Conway, B; Curescu, M; Dalgard, O; Dore, GJ; Fuster, F; Ghesquiere, W; Greenbloom, S; Janczewska, E; Kapoor, M; Knysz, B; Liu, X; Liu, Y; Luo, Y; Mazur, W; Motoc, A; Podsadecki, T; Sasadeusz, J; Shaw, D; Skoien, R; Soza, A; Streinu-Cercel, A; Sullivan, D; Tornai, I | 1 |
| Badri, PS; Dutta, S; King, JR; McGovern, BH; Menon, RM; Polepally, AR | 1 |
| Cattaneo, D; Charbe, N; Clementi, E; Gervasoni, C; Resnati, C; Sollima, S | 1 |
| Bronowicki, JP; Hézode, C | 1 |
| Abel, S; Coakley, E; Cohen, DE; Davis, JW; Dumas, EO; Dutta, S; Podsadecki, T; Waring, JF | 1 |
| Antinori, S; Calvi, E; Milazzo, L; Regalia, E; Sollima, S; Torre, A | 1 |
| Awni, WM; Badri, PS; Chiu, YL; Dutta, S; Khatri, A; Menon, RM; Podsadecki, TJ; Polepally, AR; Wang, H; Zha, J | 1 |
| Bernstein, DE; Bourgeois, S; Elkhashab, M; Feld, JJ; Fu, B; Horsmans, Y; Howieson, K; Larsen, L; Moreno, C; Pangerl, A; Polepally, AR; Poordad, F; Reindollar, RW; Shulman, NS; Tam, E; Trinh, R; Younes, Z | 1 |
| Alves, K; Badri, PS; Ding, B; Dutta, S; Menon, RM; Redman, R; Rodrigues, L; Uchiyama, N; Zha, J | 1 |
| Awni, WM; Cohen, D; Ding, B; Dutta, S; King, JR; Menon, RM; Podsadecki, TJ | 1 |
| Gonzalez, YS; Huber, C; Juday, T; Saab, S; Wang, A | 1 |
| Lim, A; Smith, MA | 1 |
| Beyer, J; Burroughs, M; Chayama, K; Collins, C; Krishnan, P; Kumada, H; Pilot-Matias, T; Redman, R; Reisch, T; Rodrigues, L; Schnell, G; Setze, C; Tripathi, R; Zhang, X | 1 |
| Busuttil, RW; Cheng, EY; Holt, CD; Saab, S | 1 |
| Husa, P | 1 |
| Asselah, T; Boyer, N; Marcellin, P; Martinot-Peignoux, M; Saadoun, D | 1 |
| Awni, W; Dutta, S; Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Wang, H | 1 |
| Fabbrizzi, A; Fognani, E; Genovesi, A; Giubilei, L; Gragnani, L; Monti, M; Petraccia, L; Piluso, A; Ranieri, J; Stasi, C; Urraro, T; Zignego, AL | 1 |
| Chiu, YL; Ding, B; Dumas, EO; Khatri, A; King, JR; Menon, RM; Podsadecki, TJ; Polepally, AR; Shuster, DL | 1 |
| Cattaneo, D; Clementi, E; Gervasoni, C; Milazzo, L; Riva, A | 1 |
| Antonov, K; Atanasova, E; Boyanova, Y; Jelev, D; Krastev, Z; Mateva, L; Petkova, T; Tomov, B; Zheleva, N | 1 |
| Abunimeh, M; Bennett, M; Bernstein, DE; Cohen, DE; Cohen, E; Khatri, A; Lawitz, E; Mantry, PS; Pockros, PJ; Podsadecki, T; Reddy, KR; Shulman, NS; Sulkowski, MS; Wang, D | 1 |
| Asselah, T; Bennett, M; Forns, X; Liu, L; Moller, J; Pedrosa, M; Planas Vila, R; Reau, N; Rustgi, V; Shiffman, ML | 1 |
| Johnson, S; Marx, SE; Misurski, D; Parisé, H; Saab, S; Sanchez Gonzalez, Y; Virabhak, S; Wang, A | 1 |
| Flisiak, R; Parfieniuk-Kowerda, A; Łucejko, M | 1 |
| Gopalakrishnan, S; Khatri, A; Menon, R; Mensing, S; Redman, R; Zha, J | 1 |
| Cattaneo, D; D'Avolio, A; Gervasoni, C; Micheli, V; Milazzo, L; Sollima, S | 1 |
| Awni, W; Dutta, S; Khatri, A; Menon, R; Mensing, S; Podsadecki, T | 1 |
| Badri, PS; Eckert, D; Menon, RM; Mensing, S; Polepally, AR | 1 |
| Filipovic, I; Johnson, SJ; Misurski, D; Parisé, H; Samp, JC; Virabhak, S | 1 |
| Badri, P; de Morais, SM; Fischer, V; Kavetskaia, O; Lee, AJ; Ma, J; Menon, R; Serby, M; Shen, J; Surber, B; Sydor, J | 1 |
| Brainard, DM; Gane, EJ; Hyland, RH; McHutchison, JG; Schwabe, C; Stamm, LM; Stedman, CA; Svarovskaia, E; Yang, Y | 1 |
| Berry, K; Beste, LA; Chang, MF; Green, PK; Ioannou, GN; Lowy, E; Su, F; Tsui, JI | 1 |
| Backus, LI; Belperio, PS; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Awni, WM; Badri, PS; Coakley, EP; Ding, B; Dutta, S; Menon, RM; Parikh, A | 1 |
| Awni, WM; Dutta, S; Hu, B; Menon, RM; Podsadecki, TJ; Polepally, AR | 1 |
| Tanaka, Y | 1 |
| Gopalakrishnan, SM; Khatri, A; Menon, RM; Mensing, S; Polepally, AR | 1 |
| Bryce, CL; Chidi, AP; Donohue, JM; Fine, MJ; Landsittel, DP; Myaskovsky, L; Rogal, SS; Smith, KJ; Switzer, GE; Tsung, A | 1 |
| Gonzalez, YS; Johnson, S; Juday, T; Misurski, D; Parisé, H; Saab, S; Virabhak, S; Wang, A | 1 |
| Igarashi, A; Johnson, S; Mitchell, D; Samp, JC; Virabhak, S; Yamazaki, K; Yasui, K; Yuen, C | 1 |
| Khoury, J; Saadi, T | 1 |
| Awni, WM; Dutta, S; Khatri, A; Marbury, TC; Menon, RM; Preston, RA; Rodrigues, L; Wang, H | 1 |
| Keating, GM | 1 |
| Chamorro-de-Vega, E; Collado Borrell, R; Escudero-Vilaplana, V; Fernandez-Llamazares, CM; Gimenez-Manzorro, A; Herranz, A; Ibañez-Garcia, S; Lallana Sainz, E; Lobato Matilla, E; Lorenzo-Pinto, A; Manrique-Rodriguez, S; Marzal-Alfaro, M; Ribed, A; Rodriguez-Gonzalez, CG; Romero Jimenez, RM; Sanjurjo, M; Sarobe Gonzalez, C | 1 |
| Beavers, K; Bernstein, D; Brainard, DM; Chung, RT; Davis, M; Dvory-Sobol, H; Etzkorn, K; Everson, G; Gane, EJ; Gordon, SC; Khalid, O; Kowdley, KV; Kwo, PY; Lu, S; McHutchison, JG; Nguyen, MH; Poulos, JE; Pound, D; Rodriguez-Torres, M; Stamm, LM; Stedman, CA; Tong, M; Tsai, N; Yang, JC | 1 |
| Bennett, M; Brainard, DM; Curry, M; Dvory-Sobol, H; Hawkins, T; Herring, R; Hinestrosa, F; Jacobson, I; Lawitz, E; Lu, S; McHutchison, JG; Nahass, R; Pearlman, B; Rabinovitz, M; Reau, N; Reddy, KR; Schiff, E; Sheikh, A; Shiffman, M; Stamm, LM; Tran, T; Yang, JC; Younes, Z | 1 |
| Antoniazzi, S; Bolis, M; Carnovale, C; Clementi, E; Gentili, M; Landonio, S; Magni, C; Niero, F; Radice, S | 1 |
| Khatri, A; Menon, R; Podsadecki, T; Trinh, R; Zhao, W | 1 |
| Marshall, G | 1 |
| Berak, H; Bialkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Halota, W; Horban, A; Jabłkowski, M; Janczewska, E; Jaroszewicz, J; Karpińska, E; Karwowska, K; Knysz, B; Kryczka, W; Lucejko, M; Madej, G; Mozer-Lisewska, I; Nazzal, K; Piekarska, A; Pisula, A; Rostkowska, K; Simon, K; Tomasiewicz, K; Tronina, O; Tudrujek, M; Wawrzynowicz-Syczewska, M; Wiercińska-Drapało, A; Zarębska-Michaluk, D | 1 |
| Hiensch, RJ; Oberg, CL; Poor, HD | 1 |
| Awni, WM; Dutta, S; Eckert, D; Khatri, A; Menon, RM; Mensing, S; Podsadecki, TJ; Polepally, AR; Sharma, S | 1 |
| Heger, E; Inden, S; Kaiser, R; Kalaghatgi, P; Knops, E; Neumann-Fraune, M; Schübel, N; Sierra, S | 1 |
| De Weggheleire, A; Dorlo, TP; Francque, S; Lynen, L; Meessen, B; Newton, PN; Pouget, C; Ravinetto, R; Sokkab, A; Tabernero, P | 1 |
| Ashimkhanova, A; Kaliaskarova, K; Yesmembetov, K | 1 |
| Ashby, CR; Jankovich, RD; Jodlowski, TZ; Puglisi, GM; Smith, SM | 1 |
| Basavanna, LN; Karuppasamy, R; Sequeira, VM; Veerappapillai, S; Verma, K | 1 |
| But, DY; Chan, CK; Chan, HL; Chan, KH; Fung, J; Hui, YT; Lai, CL; Lai, MS; Lam, YS; Lao, WC; Li, C; Lui, GC; Seto, WK; Tsang, OT; Wong, GL; Wong, VW; Yuen, MF | 1 |
| Huang, CF; Jang, TY; Lu, PL; Yu, ML | 1 |
| Alonso, A; Franco, A; Gentil, MA; González-Corvillo, C; Hernández-Marrero, D; Jiménez-Martín, C; Lauzurica, LR; Perelló, M; Sánchez-Fructuoso, A; Zarraga, S | 1 |
| Alqahtani, S; Calinas, F; Crawford, D; Dumas, EO; Feld, JJ; Ferenci, P; Gane, E; Gschwantler, M; Isakov, V; Jacobson, IM; King, M; Ozaras, R; Sulkowski, M; Wyles, D | 1 |
| Andreone, P; Magalotti, D; Martino, E; Masetti, M; Scuteri, A; Zoli, M | 1 |
| Horiguchi, N; Hosonuma, K; Kakizaki, S; Kobayashi, T; Kusano, M; Ohnishi, H; Okamoto, H; Sato, K; Takakusagi, S; Yamada, M; Yamazaki, Y | 1 |
| Cornberg, M; Deterding, K; Fischer, N; Grundhoff, A; Manns, MP; Schlevogt, B; Steinmann, E; Todt, D; Wedemeyer, H | 1 |
| Yu, ML | 1 |
| Aichelburg, MC; Bucsics, T; Ferenci, P; Grabmeier-Pfistershammer, K; Mandorfer, M; Peck-Radosavljevic, M; Reiberger, T; Scheiner, B; Schwabl, P; Steiner, S; Trauner, M | 1 |
| Abad, S; Albalate, M; de Sequera, P; Hernández, E; López-Gómez, JM; Macías, N; Mérida, E; Milla, M; Vega, A | 1 |
| Albillos, A; Ampuero, J; Arenas, J; Bañares, R; Calleja, JL; Crespo, J; Diago, M; Fernandez, I; García-Eliz, M; García-Samaniego, J; Gea, F; Jorquera, F; Lens, S; Llaneras, J; Llerena, S; Mariño, Z; Morillas, RM; Muñoz, R; Navascues, CA; Pascasio, JM; Perelló, C; Rincón, D; Rodriguez, CF; Ruiz-Antorán, B; Sacristán, B; Serra, MA; Simon, MA; Torras, X; Turnes, J | 1 |
| Backus, LI; Belperio, PS; Bhattacharya, D; Goetz, MB; Loomis, TP; Mole, LA; Shahoumian, TA | 1 |
| Brainard, DM; Dvory-Sobol, H; Gutierrez, J; Hyland, RH; Landaverde, C; Lawitz, E; McHutchison, JG; Poordad, F; Stamm, LM; Wells, J; Yang, Y | 1 |
| Lim, SG | 1 |
| Badri, PS; Dutta, S; Menon, RM; Shuster, DL | 1 |
| D'Offizi, G; Gasbarrini, A; Gianserra, L; Lionetti, R; Pasquazzi, C; Pompili, M; Ponziani, FR; Siciliano, M | 1 |
| King, JR; Menon, RM | 1 |
| Flisiak, R; Flisiak-Jackiewicz, M | 1 |
| Adeyemi, O; Bhatti, L; Hu, YB; Khatri, A; King, JR; Lalezari, J; Ruane, P; Saag, M; Shulman, NS; Trinh, R; Viani, RM; Wyles, D | 1 |
| Baumgarten, A; Berg, T; Buggisch, P; Christensen, S; Deterding, K; Hettinger, J; Heyne, R; Hinrichsen, H; Hüppe, D; John, C; Kleine, H; König, B; Lutz, T; Mauss, S; Sarrazin, C; Schott, E; Stein, K; Teuber, G; van Bömmel, F; Wedemeyer, H; Welzel, TM; Zimmermann, T | 1 |
| DiFrancesco, R; Hagler, CE; Morse, GD; Ocque, AJ; Talal, AH | 1 |
| Awni, W; DaSilva-Tillmann, B; Dutta, S; Lin, CW; Liu, W; Menon, R; Podsadecki, T; Shulman, N | 1 |
| Bolewska, B; Buivydiene, A; Durlik, M; Flisiak, R; Jabłkowski, M; Jakutiene, J; Karpińska, E; Karwowska, KM; Katzarov, K; Kupcinskas, L; Pisula, A; Rostkowska, K; Simonova, M; Tolmane, I; Tronina, O; Wawrzynowicz-Syczewska, M | 1 |
| Agarwal, K; Asselah, T; Berg, T; Bhandari, BR; Borgia, SM; Brainard, DM; Bräu, N; Davis, M; Dore, GJ; Dvory-Sobol, H; Feld, JJ; Foster, GR; Gane, EJ; Hyland, RH; Jacobson, IM; Lawitz, E; McHutchison, JG; Nahass, RG; Pearlman, B; Roberts, SK; Ruane, PJ; Shafran, SD; Stamm, LM; Stedman, CAM; Subramanian, GM; Svarovskaia, E; Thompson, AJ; Willems, BE; Workowski, KA; Zhu, Y | 1 |
| Asselah, T; ElKhashab, M; Feld, JJ; Ferenci, P; Hassanein, T; Hézode, C; Mobashery, N; Moreno, C; Papatheodoridis, G; Pilot-Matias, T; Qaqish, RB; Redman, R; Yu, Y; Zeuzem, S | 1 |
| Allam, N; Asselah, T; Doss, W; Esmat, G; Hall, C; Hassany, M; Mobashery, N; Mohey, MA; Qaqish, RB; Redman, R; Shiha, G; Soliman, R; Waked, I; Yosry, A; Zayed, N | 1 |
| Asselah, T; Cohen, DE; Dumas, EO; Feld, JJ; Forns, X; Hazzan, R; Lu, W; Pilot-Matias, T; Shaw, D; Welzel, TM; Zeuzem, S | 1 |
| Bollipo, S; Cheng, W; Chivers, S; Dore, G; Fragomeli, V; Galhenage, S; Gazzola, A; George, J; Gow, P; Iser, D; Jones, T; Levy, M; Lubel, J; MacQuillan, G; Mitchell, JL; Nazareth, S; Pianko, S; Roberts, SK; Sasadeusz, J; Strasser, S; Stuart, KA; Thompson, A; Tse, E; Wade, A; Weltman, M; Wigg, A; Zekry, A | 1 |
| Bao, Y; Calleja, JL; Craxí, A; Dieterich, D; Flisiak, R; Martinez, M; Pangerl, A; Roberts, SK; Wedemeyer, H; Zhang, Z; Zuckerman, E | 1 |
| Bow, DAJ; de Morais, SM; Fischer, V; Kavetskaia, O; Liu, J; Nijsen, MJMA; Shebley, M; Sydor, J | 1 |
| Aghemo, A; Alberti, A; Antinori, A; Ascione, A; Bruno, R; Bruno, S; Chirianni, A; Craxì, A; Gaeta, GB; Giannini, EG; Marzioni, M; Merli, M; Messina, V; Montilla, S; Pani, L; Perno, CF; Petta, S; Puoti, M; Raimondo, G; Rendina, M; Russo, P; Silberstein, FC; Villa, E; Zignego, AL | 1 |
| Alves, K; Burroughs, M; Chayama, K; Kato, K; Kumada, H; Pilot-Matias, T; Redman, R; Rodrigues, L; Sato, K; Setze, C; Suzuki, F; Toyoda, H; Zhang, X | 1 |
| Bansal, MB; Bourlière, M; Brainard, DM; Buggisch, P; Cooper, CL; Curry, MP; de Lédinghen, V; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Huang, KC; Hyland, RH; Kowdley, KV; Landis, CS; Manns, MP; McHutchison, JG; Pianko, S; Ramji, A; Ravendhran, N; Reddy, KR; Schiff, ER; Stamm, LM; Strasser, SI; Subramanian, GM; Svarovskaia, E; Tong, M; Tran, TT; Verna, EC; Vierling, JM; Younes, ZH; Zeuzem, S; Zhang, J | 1 |
| Czarny, P; Jabłkowski, M; Karwowski, B; Majchrzak, K; Merecz-Sadowska, A; Śliwiński, T; Szemraj, J | 1 |
| Amemiya, M; Hayashi, N; Koshima, Y; Kuriyama, S; Matsuyama, M; Morisawa, N; Satoh, JI; Yokoo, T | 1 |
| Cohen, DE; Cohen, E; Feld, JJ; Foster, GR; Fried, MW; Larsen, L; Mobashery, N; Nelson, DR; Poordad, F; Tatsch, F; Wedemeyer, H | 1 |
| Aikata, H; Chayama, K; Daijo, K; Hayes, CN; Honda, F; Honda, Y; Imamura, M; Kan, H; Kawakami, Y; Kawaoka, T; Kobayashi, T; Miki, D; Mori, N; Morio, K; Nagaoki, Y; Nakahara, T; Nakamura, Y; Ochi, H; Takaki, S; Teraoka, Y; Tsuge, M; Tsuji, K | 1 |
| Chen, SC; Chen, YL; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Lin, KH; Lin, ZY; Yeh, ML; Yu, ML | 1 |
| Jacobson, IM; Voaklander, R | 1 |
| Ashur, Y; Balicer, R; Braun, M; Brufman, I; Hammerman, A; Hoshen, M; Leventer-Roberts, M; Lieberman, N | 1 |
| Bellissant, E; Ben Ali, Z; Boglione-Kerrien, C; Guyader, D; Jezequel, C; Lemaitre, F; Tron, C; Verdier, MC | 1 |
| Antón, MD; Ferrando, I; Latorre, P; Moreno Osset, E; Pascual, A; Polanco, A | 1 |
| Arias, A; Barreiro, P; Benítez-Gutiérrez, L; Carrasco, I; de Mendoza, C; Peña, JM; Soriano, V | 1 |
| Chen, DS; Chen, PJ; Hong, CM; Kao, JH; Liu, CH; Liu, CJ; Su, TH; Tseng, TC; Yang, HC | 1 |
| Abunimeh, M; Agarwal, K; Charafeddine, M; Cohen, DE; Cohen, E; Foster, GR; Fu, B; Gane, E; Pilot-Matias, T; Pothacamury, RK; Shafran, SD; Shaw, D | 1 |
| Alves, K; Beyer, J; Burroughs, M; Chayama, K; Collins, C; Dekhtyar, T; Irvin, M; Krishnan, P; Kumada, H; Pilot-Matias, T; Redman, R; Reisch, T; Rodrigues, L; Schnell, G; Setze, C; Tripathi, R | 1 |
| Abdel-Daim, MM; Abushouk, AI; Ahmed, H; Loutfy, SA; Menshawy, A; Mohamed, A; Negida, A | 1 |
| Abou-Samra, AB; Butt, AA; Simon, TG; Yan, P | 1 |
| Rostkowska, K; Simon, K; Szymanek-Pasternak, A | 1 |
| Arama, V; Brisc, C; Caruntu, F; Cijevschi, C; Curescu, M; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Simionov, I; Sirli, R; Sporea, I; Stanciu, C; Trifan, A | 1 |
| Cole, J; Stark, JE | 1 |
| Alves, K; Atarashi, T; Burroughs, M; Chayama, K; Eguchi, Y; Karino, Y; Kato, K; Kawakami, Y; Krishnan, P; Kumada, H; Naganuma, A; Oberoi, RK; Pilot-Matias, TJ; Pugatch, DL; Redman, R; Sato, K; Seike, M; Suzuki, F; Takei, Y; Watanabe, T; Xie, W; Yoshiji, H | 1 |
| Fauler, G; Kessler, HH; Leber, B; Mangge, H; Posch, A; Rainer, F; Spindelboeck, W; Stadlbauer, V; Stauber, RE; Streit, A | 1 |
| Chodick, G; Koren, G; Mehta, D; Pinsky, B; Samp, JC; Shalev, V; Weil, C | 1 |
| Ardèvol, M; Carrión, JA; Gallego, A; González-Colominas, E; Lens, S; Londoño, MC; López, D; Mariño, Z; Mojal, S; Morillas, RM; Pagès, N; Solà, R; Torras, X | 1 |
| Abraham, GM; Spooner, LM | 1 |
| Chen, SC; Chuang, WL; Dai, CY; Hsieh, MH; Huang, CF; Huang, CI; Huang, JF; Liang, PC; Lin, YH; Lin, ZY; Yang, JF; Yeh, ML; Yu, ML | 1 |
| Birnkrant, D; Chan-Tack, K; Naeger, LK; Qi, K; Struble, K | 1 |
| Aschenbrenner, DS | 1 |
| Agrati, C; Ammassari, A; Antinori, A; Bellagamba, R; Fabbri, G; Libertone, R; Lupi, F; Mastrorosa, I; Notari, S; Tempestilli, M; Timelli, L; Zaccarelli, M | 1 |
| Kottilil, S; O'Brien, TR; Pfeiffer, RM | 1 |
| Chahine, EB; Childs-Kean, LM; Kelley, D | 1 |
| Bak, A; Bobal, P; Havelkova, M; Imramovsky, A; Jampilek, J; Kauerova, T; Kollar, P; Kozik, V; Oravec, M; Pizova, H; Stepankova, S | 1 |
| Bourliere, M; Cooper, C; Flamm, S; Gordon, S; Hunt, S; Jacobson, I; Kowdley, K; Mann, MP; Reddy, KR; Stepanova, M; Younossi, I; Younossi, ZM; Zeuzem, S | 1 |
| Anderson, R; Avellar, AM; Castro, R; Hyde, C; Jorge, MJ; Mujica-Mota, R; Perazzo, H; Romero, C; Silva, JC; Silva, PS; Veloso, VG | 1 |
| Asselah, T; Foster, GR; Gane, EJ; Henry, L; Jacobson, IM; Lawitz, E; Pearlman, B; Racila, A; Roberts, SK; Stepanova, M; Thompson, AJ; Welzel, TM; Willems, BE; Younossi, I; Younossi, ZM | 1 |
| Besandre, R; Liu, HW | 1 |
| Komatsu, H; Miyata, N; Tachikawa, N; Yoshimura, Y | 1 |
| Buti, M; Chen, Q; Esteban, JI; Esteban, R; Garcia-Cehic, D; Gregori, J; Llorens, M; Nieto-Aponte, L; Ordeig, L; Perales, C; Quer, J; Riveiro-Barciela, M; Rodriguez-Frias, F; Soria, ME | 1 |
| Hirayama, T; Honda, A; Ikegami, T; Kohjima, M; Matsuzaki, Y; Miyazaki, T; Nakamuta, M; Yara, SI | 1 |
| Afghani, AA; Alghamdi, AS; Alghamdi, MN; AlMousa, A; Alswat, K; AlZanbagi, A; Aseeri, M; Assiri, AM; Babatin, MA; Sanai, FM | 1 |
| Bao, Y; Grunow, N; Hudgens, S; Mehta, D; Pinsky, B; Saab, S | 1 |
| Boglione, L; Cariti, G; Cusato, J; D'Avolio, A; De Nicolò, A; Di Perri, G; Pinna, SM | 1 |
| Hussar, DA | 1 |
| Chamorro-de-Vega, E; De Lorenzo-Pinto, A; Escudero-Vilaplana, V; Gimenez-Manzorro, A; Herranz-Alonso, A; Iglesias-Peinado, I; Rodriguez-Gonzalez, CG; Sanjurjo Saez, M | 1 |
| Younossi, ZM | 1 |
| Danta, M; Sanagapalli, S | 1 |
| Muñoz-Medina, L; Navarro-Navarro, I; Navarro-Triviño, FJ; Ruiz-Villaverde, R | 1 |
| Asatryan, A; Asselah, T; Bourlière, M; Bruck, R; Chuang, WL; Dore, GJ; Feld, JJ; Felizarta, F; Flamm, S; Flisiak, R; Foster, GR; Fu, B; Fuster, F; Gane, E; Kaita, K; Kort, J; Kwo, P; Lin, CW; Liu, R; Mensa, FJ; Ng, TI; Paik, SW; Pilot-Matias, T; Pol, S; Poordad, F; Puoti, M; Roberts, SK; Ruane, PJ; Sepulveda-Arzola, G; Soto-Malave, R; Stedman, CA; Tam, E; Trinh, R; Vargas, HE; Vierling, J; Wang, S; Wedemeyer, H; Zeuzem, S | 1 |
| Bernstein, DE; Feld, JJ; Ferenci, P; Larsen, L; Tatsch, F; Vlierberghe, HV; Younes, Z | 1 |
| Bataga, S; Brisc, C; Caruntu, FA; Chiriac, S; Cijevschi Prelipcean, C; Curescu, M; Gheorghe, L; Girleanu, I; Goldis, A; Iacob, S; Miftode, E; Mihai, C; Preda, C; Rogoveanu, I; Singeap, AM; Sporea, I; Stanciu, C; Stefanescu, G; Trifan, A | 1 |
| Borba, HHL; Ferreira, VL; Leonart, LP; Pontarolo, R; Tonin, FS | 1 |
| Collado, A; de Los Santos, I; Macías, J; Mancebo, M; Merino, D; Morano-Amado, LE; Palacios, R; Pérez, AB; Pérez-Pérez, M; Pineda, JA; Ríos, MJ; Rivero, A; Rivero-Juárez, A; Téllez, F | 1 |
| Cao, Y; Chen, D; Gai, K; Liu, B; Liu, X; Lu, D; Lu, Q; Qin, H; Shen, H; Song, W; Wang, X; Xu, H; Zhang, Y | 1 |
| Aghemo, A; Baldanti, F; Borghi, M; D'Ambrosio, R; De Nicola, S; Degasperi, E; Lampertico, P; Lunghi, G; Novazzi, F; Paolucci, S; Perbellini, R | 1 |
| Caroprese, M; Coppola, N; De Pascalis, S; Guerrera, B; Iovinella, V; Macera, M; Masarone, M; Minichini, C; Occhiello, L; Starace, M; Vitrone, M | 1 |
| Deeks, ED; Heo, YA | 1 |
| Abdel-Gabbar, M; Abdel-Moneim, A; Aboud, A; Ramadan, M; Zanaty, M | 1 |
| Alcaro, S; Artese, A; Barreca, GS; De Siena, M; Di Salvo, S; Fabiani, F; Focà, A; Giancotti, F; Gravina, T; Liberto, MC; Marano, V; Marascio, N; Pavia, G; Perrotti, N; Reale, M; Romeo, I; Talarico, C; Torti, C | 1 |
| Akuta, N; Arase, Y; Fujiyama, S; Hosaka, T; Ikeda, K; Kawamura, Y; Kobayashi, M; Kumada, H; Kuwano, T; Saitoh, S; Sezaki, H; Suzuki, F; Suzuki, Y | 1 |
| Beyer, J; Collins, C; Dekhtyar, T; Hall, C; Irvin, M; Krishnan, P; Mobashery, N; Pilot-Matias, T; Redman, R; Reisch, T; Schnell, G; Tripathi, R; Yu, Y | 1 |
| Cory, TJ; Gong, Y; Kodidela, S; Kumar, S; Mu, Y | 1 |
| Applegate, TL; Bhagani, S; Cooke, G; Dore, GJ; Gane, E; Grebely, J; Marks, P; Martinello, M; Matthews, GV; Nelson, M; Orkin, C; Pagani, N; Petoumenos, K; Tu, E | 1 |
| Hashimoto, S; Hayashi, K; Nakagawa, Y; Saito, K; Takahashi, K; Takamura, M; Takeuchi, S; Tanabe, Y; Tasaki, M; Terai, S; Tomita, Y; Yamagiwa, S; Yoshida, T | 1 |
| Chmelova, K; Frankova, S; Kreidlova, M; Merta, D; Senkerikova, R; Sperl, J | 1 |
| Bogomolov, PO; Chen, X; Enejosa, JV; Isakov, V; Maevskaya, MV; Ogurtsov, P; Paduta, D; Pasechnikov, V; Shulman, NS; Viani, RM; Znoyko, O | 1 |
| Honma, T; Imai, M; Ishikawa, T; Iwanaga, A; Nozawa, Y; Owaki, T; Sano, T; Sato, H; Seki, K; Yoshida, T | 1 |
| Abe, K; Hoshino, T; Kawakami, T; Miyasaka, A; Murakami, A; Ohuchi, K; Sawara, K; Takikawa, Y; Watanabe, D; Yoshida, T; Yoshida, Y | 1 |
| Aghemo, A; Ascione, A; Bruno, S; Craxì, A; De Luca, M; Fontanella, L; Gasbarrini, A; Giannini, EG; Izzi, A; Marzioni, M; Melazzini, M; Messina, V; Montilla, S; Orlandini, A; Petta, S; Puoti, M; Sangiovanni, V; Trotta, MP; Villa, E; Zignego, AL | 1 |
| Waked, I | 1 |
| Bourlière, M; Brainard, DM; Curry, MP; Dvory-Sobol, H; Gordon, SC; Hyland, RH; Landis, CS; Manns, MP; McHutchison, JG; Ravendhran, N; Reddy, KR; Schiff, ER; Sepe, TE; Serfaty, L; Stamm, LM; Subramanian, GM; Thompson, AJ; Tran, TT; Zhang, J | 1 |
| Summers, BB | 1 |
| Dolman, GE; Gelson, WT; Selby, P | 1 |
| Berak, H; Białkowska, J; Bolewska, B; Fleischer-Stępniewska, K; Flisiak, R; Garlicki, A; Janczewska, E; Karpińska, E; Karwowska, K; Nazzal, K; Piekarska, A; Simon, K; Tomasiewicz, K; Tronina, O; Tuchendler, E; Zarębska-Michaluk, D; Łucejko, M | 1 |
| Bourliere, M; Gordon, SC; Manns, MP; Racila, A; Reddy, R; Schiff, E; Stepanova, M; Tran, T; Younossi, I; Younossi, ZM | 1 |
| Alami, NN; Allam, N; Esmat, G; Fouad, R; Hall, C; Hassany, M; Kopecky-Bromberg, S; Mobashery, N; Mohey, M; Qaqish, RB; Shiha, G; Soliman, R; Waked, I | 1 |
| Alves, K; Ding, B; Luo, Y; Menon, RM; Mobashery, N; Wang, H; Yu, C; Zha, J; Zhao, W | 1 |
| Cerban, R; Ester, C; Gheorghe, C; Gheorghe, L; Iacob, R; Iacob, S; Pietrareanu, C; Popescu, I | 1 |
| Giménez-Manzorro, A; Herranz-Alonso, A; Matilla-Peña, A; Revuelta-Herrero, JL; Sanjurjo-Sáez, M | 1 |
| Andersen, ES; Bukh, J; Christensen, PB; Fahnøe, U; Gerstoft, J; Kjær, MS; Laursen, AL; Mössner, B; Pedersen, MS; Røge, BT; Schønning, K; Sølund, C; Weis, N | 1 |
| Arai, K; Honda, M; Horii, R; Iida, N; Kaneko, S; Kawaguchi, K; Kitahara, M; Kitamura, K; Mizukoshi, E; Nio, K; Orita, N; Sakai, Y; Shimakami, T; Sunagozaka, H; Takatori, H; Terashima, T; Yamashita, T | 1 |
| Abdel-Razek, W; Waked, I | 1 |
| Bourliere, M; Brainard, DM; Camus, G; Cooper, CL; Doehle, BP; Dvory-Sobol, H; Flamm, SL; Gordon, SC; Hyland, RH; Kowdley, KV; Manns, MP; Martin, R; Mo, H; Reddy, KR; Roberts, SK; Sarrazin, C; Stamm, LM; Svarovskia, E; Zeuzem, S | 1 |
| Chen, WT; Chen, YC; Hsieh, YC; Huang, CH; Jeng, WJ; Lin, CY; Lin, SM; Sheen, IS; Tai, DI; Teng, W | 1 |
| Antón, MD; Badia, E; Cabezas, J; Calleja, JL; Carrión, JA; Castro, JL; Cordero, P; De Cuenca, B; De la Vega, J; Diago, M; Gea, F; Lens, S; Molina, E; Montoliu, S; Moreno, J; Moreno, JM; Morillas, RM; Olveira, A; Pascasio, JM; Puigvehí, M; Salmerón, J; Sánchez-Ruano, JJ; Torras, X; Turnes, J; Viu, A | 1 |
| Abdel-Aziz, EM; Abdel-Malek, MO; Hashim, AA; Hetta, HF; Mekky, MA; Morsy, KH; Osman, HA | 1 |
| Kottilil, S; Mathur, P; Wilson, E | 1 |
| Hinds, AE; Pearlman, BL | 1 |
| Arias, M; Belmar, L; González, LN; Laguno, M; Llovet, LP; Londoño, MC; Maduell, F; Mallolas, J; Martínez-Rebollar, M; Ojeda, R; Rodas, L; Rossi, F; Ugalde, J | 1 |
| Lee, TY; Yang, SS | 1 |
| Eibl, MM; Müller, CJ; Wolf, HM | 1 |
| Applegate, TL; Bruggmann, P; Bruneau, J; Castro, E; Conway, B; Cooper, C; Crawford, S; Cunningham, EB; Dalgard, O; Daulouede, JP; Dore, GJ; Dunlop, A; Erratt, A; Feld, JJ; Fraser, C; Gane, E; Grebely, J; Hajarizadeh, B; Hellard, M; Kronborg, I; Lacombe, K; Marks, P; Matthews, GV; Moriggia, A; Petoumenos, K; Powis, J; Schmid, P; Shaw, D; Stedman, C | 1 |
| Adamek, B; Baka-Ćwierz, B; Belica-Wdowik, T; Berak, H; Białkowska-Warzecha, J; Buczyńska, I; Citko, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracki, W; Dybowska, D; Flisiak, R; Garlicki, A; Gietka, A; Halota, W; Horban, A; Janczewska, E; Jaroszewicz, J; Laurans, Ł; Lorenc, B; Mazur, W; Piekarska, A; Simon, K; Sitko, M; Socha, Ł; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Wawrzynowicz-Syczewska, M; Zarębska-Michaluk, D | 1 |
| Bondin, M; Cacoub, P; Fabrizi, F; Negro, F | 1 |
| Cenderello, G; Di Biagio, A; Taramasso, L | 1 |
| Li, K; Liu, JP; Ning, HB; Shang, J; Xiao, EH | 1 |
| Hsiang, JC; Kumar, R; Tan, J; Thurairajah, PH | 1 |
| Baba, M; Kawagishi, N; Kimura, M; Maehara, O; Morikawa, K; Nakai, M; Nakamura, A; Natsuizaka, M; Ogawa, K; Ohara, M; Sakamoto, N; Shigesawa, T; Shimazaki, T; Sho, T; Suda, G; Suzuki, K; Umemura, M | 1 |
| Affonso-de-Araújo, ES; Álvares-da-Silva, MR; Alves, K; Brandão-Mello, CE; Cheinquer, H; Coelho, HS; Cohen, DE; Ferraz, ML; Ferreira, PRA; Furtado, J; Lari, SA; Liu, L; Martinelli, A; Mendes-Correa, MC; Nunes, EP; Parana, R; Pessoa, MG; Pilot-Matias, T; Ramalho-Madruga, JV; Shulman, NS; Silva, G; Tripathi, R | 1 |
| Fan, H; Fu, Z; Huang, P; Tian, T; Wang, Y; Wu, J; Xia, X; Ye, X; Yue, M; Zhang, Y | 1 |
| Brainard, DM; Dvory-Sobol, H; Gane, EJ; Hyland, RH; Nyberg, L; Ruane, P; Shafran, S; Shao, J; Stamm, LM; Strasser, SI; Tran, T | 1 |
| Altıntaş, E; Ateş, F; Özdoğan, O; Sezgin, O; Üçbilek, E; Yaraş, S | 1 |
| Asiller, ÖÖ; Ateş, K; Aygen, B; Erdem, İ; Karaali, R; Karakaya, F; Örmeci, N; Sezgin, O; Turan, D; Yaras, S; Yildiz, O | 1 |
| Althoff, CE; Bergfeld, L; Brakemeier, S; Budde, K; Duerr, M; Eckardt, KU; Glander, P; Halleck, F; Lehner, LJ; Marticorena Garcia, SR; Sack, I; Schrezenmeier, EV | 1 |
| Boyacıoğlu, AS; Çolak, T; Dağlı, Ü; Haberal, M; Hilmioğlu, F; Öcal, S; Özer Etik, D; Selçuk, H; Suna, N | 1 |
| Back, D; Bondin, M; Bourgeois, S; Buggisch, P; Charafeddine, M; Crown, E; Curescu, M; Dorr, P; Ferenci, P; Flisiak, R; Kleine, H; Larrey, D; Marra, F; Norris, S | 1 |
| Bladowska, J; Ejma, M; Fleischer-Stępniewska, K; Inglot, M; Knysz, B; Marciniewicz, E; Małyszczak, K; Pawłowski, T; Podgórski, P; Rymer, W; Sąsiadek, M; Waliszewska-Prosół, M; Żelwetro, A | 1 |
| Dabes, H; ElSaeed, K; ElSerafy, M; ElShazly, Y; Hamed, S; Omar, H; Saad, Y; Said, M; Soliman, Z | 1 |
| Abunimeh, M; Bennett, M; Cohen, DE; Cohen, E; Everson, G; Phillips, RW; Pilot-Matias, T; Poordad, F; Reindollar, RW; Sepe, TE; Siddique, A; Sullivan, JG; Younes, Z | 1 |
| Chen, CY; Chen, DS; Chen, PJ; Cheng, PN; Chiu, YC; Fang, YJ; Hsieh, TY; Kao, JH; Lin, CL; Liu, CH; Liu, CJ; Peng, CY; Shih, YL; Su, TH; Yang, HC; Yang, SS | 1 |
| Chen, CH; Hu, TH; Hung, CH; Lee, YC; Lu, SN; Wang, JH | 1 |
| Bukh, J; Dietz, J; Fahnøe, U; Filskov, J; Fourati, S; Ghanem, L; Gottwein, JM; Humes, D; Jensen, SB; Krarup, H; Pawlotsky, JM; Pedersen, MS; Pham, LV; Pihl, AF; Ramirez, S; Sarrazin, C; Schønning, K; Serre, SBN; Sølund, CS; Tang, Q; Weis, N | 1 |
| Bank, L; Bernstein, D; Epstein, M; Krishnan, P; Lucey, MR; Martinez, M; Nelson, DR; Pockros, PJ; Polepally, AR; Poordad, F; Ravendhran, N; Reindollar, R; Sedghi, S; Trinh, R; Unnebrink, K | 1 |
| Aghemo, A; Parigi, TL; Torres, MCP | 1 |
| Angulo-Diaz, V; Lim, JK; Mandimika, C; Maughan, A; Ogbuagu, O; Sadigh, K; Villanueva, M | 1 |
| Chen, CH; Chien, RN; Hsieh, SY; Hu, TH; Hung, CH; Lin, CL; Lin, CY; Lu, SN; Sheen, IS; Tung, SY | 1 |
| Hinds, A; Pearlman, B; Perrys, M | 1 |
| Amador, J; Di Bisceglie, AM; Evon, DM; Fried, MW; Golin, CE; Lim, JK; Lok, AS; Nelson, DR; Rajender Reddy, K; Reau, N; Reeve, BB; Sarkar, S; Serper, M; Sterling, RK; Stewart, PW | 1 |
| Skorokhodova, N; Tsarova, O; Zhyvytsia, D | 1 |
| Appleby, T; Barauskas, O; Chan, K; Cheng, G; Jin, D; Karki, KK; Katana, A; Kato, D; Kobayashi, T; Link, JO; Martinez, R; Ramey, K; Sangi, M; Schrier, A; Schultz, BE; Siegel, D; Taylor, JG; Tran, CV; Villaseñor, AG; Vivian, R; Wang, K; Wang, Y; Yang, CY; Yang, ZY; Zablocki, J; Zipfel, S | 1 |
| Chua, J; Comstock, E; Covert, E; Emmanuel, B; Hoffmann, J; Husson, J; Kattakuzhy, S; Kottilil, S; Masur, H; Mathur, P; Price, A; Rosenthal, E; Tang, L; Wilson, E | 1 |
| Cooke, G; Fawsitt, CG; Vickerman, P; Welton, NJ | 1 |
| Antonio Carrión, J; Arenas, J; Arencibia, A; Badia, E; Bernal, V; Buti, M; Cachero, A; Carmona, I; Conde, I; Delgado, M; Diago, M; Esteban, R; Fernández, I; Fernández-Bermejo, M; Fernández-Rodríguez, C; Figueruela, B; García-Samaniego, J; Gea, F; González-Santiago, JM; Hernández-Guerra, M; Iñarrairaegui, M; Lens, S; Llaneras, J; Llerena, S; Luis Calleja, J; María Morillas, R; Mariño, Z; Montoliu, S; Pascasio, JM; Riveiro-Barciela, M; Rosales, JM; Torras, X; Turnes, J | 1 |
| Baicus, C; Constantinescu, I; Diculescu, M; Dumitru, R; Gavrila, D; Istratescu, D; Manuc, M; Manuc, T; Oproiu, A; Preda, CM; Sandra, I; Tieranu, C; Vasilescu, C; Voiosu, T | 1 |
| Alados-Arboledas, JC; Aldámiz-Echevarría, T; Casado, M; Chueca, N; García, F; García-Bujalance, S; García-Deltoro, M; Lara-Pérez, MM; Martínez-Sapiña, AM; Merino, D; Pascasio, JM; Pérez, AB; Pineda, JA; Poyato, A; Rivero-Juárez, A; Rosales-Zábal, JM; Salmerón, J; Téllez, F; Vera-Méndez, FJ; Vivancos-Gallego, MJ | 1 |
| Bakr, MA; El Maghrabi, HM; Elbasiony, MA; Eldahshan, KF; Elmowafy, AY; Matter, YE; Refaie, AF; Rostaing, L; Saleh, HH; Shiha, GE | 1 |
| Akarca, US; Danış, N; Ersöz, G; Günşar, F; Karasu, Z; Özkahya, M; Toz, H; Turan, İ; Ünal, N; Yılmaz, M | 1 |
| Ahumada, A; Aldamiz-Echevarría, T; Baliellas, C; Barril, G; Benlloch, S; Bonet, L; Carmona, I; Castaño, MA; Castro, Á; de Álvaro, C; de Los Santos, I; Delgado, M; Devesa-Medina, MJ; García-Buey, L; García-Samaniego, J; Gea-Rodríguez, F; González-Parra, E; Gutiérrez, ML; Jiménez-Pérez, M; Laguno, M; Londoño, MC; Losa, JE; Mallolas, J; Manzanares, A; Martín-Granizo, I; Montero-Alonso, M; Montes, ML; Morán-Sánchez, S; Morano, L; Muñoz-Gómez, R; Navascués, CA; Polo-Lorduy, B; Riveiro-Barciela, M; Rivero, A; Roget, M; Serra, MÁ | 1 |
| Berg, T; Boeker, KHW; Buggisch, P; C-Registry, GH; Günther, R; Hinrichsen, H; Klinker, H; Manns, MP; Mauss, S; Müller, T; Serfert, Y; Wiegand, J; Zeuzem, S | 1 |
| Biondi, B; Brustolin, L; Fregona, D; Marchiò, L; Nardon, C; Pettenuzzo, N; Pontisso, P; Quarta, S | 1 |
| Abdelghani, R; Elkholy, S; Elmeligui, A; Farouk, F; Ibahim, S; Mogawer, S; Wahba, D | 1 |
| Aguilar, P; Aldámiz-Echevarría, T; Andrade, RJ; Carnicer, F; Carrión, JA; Chimeno-Hernández, S; Delgado, M; Escarda, A; Espinosa, N; Estébanez, Á; Gallego, A; García-Buey, L; Hernández-Guerra, M; Hijona, L; Izquierdo, S; Jou, A; Lorente, S; Magaz, M; Manuel Sousa, J; Manzanares, A; Martín-Granizo, I; Mateos-Muñoz, B; Menéndez, F; Morán-Sánchez, S; Morano, L; Moreno-Planas, JM; Morillas, RM; Polo-Lorduy, B; Pulido, F; Rico, M; Rincón, D; Rodríguez, M; Rubín, Á; Salmerón, J; Sampedro, B; Sánchez Antolín, G; Vergara, M; Von-Wichmann, MÁ; Zozaya, JM | 1 |
| Aikata, H; Chayama, K; Hiramatsu, A; Imamura, M; Kawaoka, T; Morio, K; Murakami, E; Nakahara, T; Ohya, K; Tsuge, M; Yamauchi, M | 1 |
| Baka-Ćwierz, B; Belica-Wdowik, T; Białkowska, J; Buczyńska, I; Citko, J; Czauż-Andrzejuk, A; Deroń, Z; Dobracka, B; Dybowska, D; Flisiak, R; Garlicki, A; Halota, W; Janczewska, E; Jaroszewicz, J; Klapaczyński, J; Krygier, R; Laurans, Ł; Lorenc, B; Mazur, W; Pabjan, P; Pawłowska, M; Piekarska, A; Simon, K; Sitko, M; Tomasiewicz, K; Tronina, O; Tudrujek-Zdunek, M; Zarębska-Michaluk, D | 1 |
| Ali, A; Henes, M; Hou, S; Kosovrasti, K; Kurt Yilmaz, N; Leidner, F; Schiffer, CA; Timm, J | 1 |
| Belvisi, L; Borlandelli, V; Corno, C; Dal Corso, A; Gennari, C; Perego, P; Pignataro, L | 1 |
| Chung, RT; Holmes, JA | 1 |
| Iliescu, EL; Mercan-Stanciu, A; Toma, L | 1 |
| Abu Hassan, MR; Gonzalez, YS; Ong, SC; Shafie, AA; Virabhak, S | 1 |
| Akhan, S; Ergun, NC; Köse, Ş; Onlen, Y; Tatar, B; Turken, M; Yılmaz, Y | 1 |
| Alston-Smith, B; Anthony, DD; Balagopal, A; Cohen, DE; Morse, GD; Quinn, J; Santana-Bagur, JL; Smeaton, LM; Sulkowski, MS; Talal, AH; Venuto, CS; Vu, V; Wyles, DL | 1 |
| Ben-Ari, Z; Bruck, R; Cohen-Ezra, O; Deutsch, L; Gozlan, Y; Houri, I; Issachar, A; Katchman, H; Menachem, Y; Mor, O; Shibolet, O; Shlomai, A; Veitsman, E; Zelber-Sagi, S | 1 |
| Abd-Elsalam, SM; Abdulaziz, BA; El Attar, IH; El Kassas, M; Emadeldeen, M; Said, EM | 1 |
| Bajis, S; Dore, GJ; Martinello, M | 1 |
| Alston-Smith, BL; Anthony, DD; Balagopal, A; Bhattacharya, D; Cohen, DE; Damjanovska, S; Kowal, CM; Shive, CL; Smeaton, LM; Sulkowski, MS; Wyles, DL | 1 |
| Agarwal, K; Bestwick, J; Drysdale, K; Elsharkawy, AM; Forton, D; Foster, GR; Gelson, W; Mahomed, F; Mutimer, D; Ntuli, Y; Townley, C | 1 |
| Hsu, EK; Jolley, CD; Jonas, MM; Leung, DH; Liu, L; Lobritto, SJ; Molleston, JP; Narkewicz, MR; Rosenthal, P; Wen, J; Yao, BB; Zha, J | 1 |
| Abufreha, N; Dahari, H; Dizengof, V; Etzion, O; Nevo-Shor, A; Yardeni, D | 1 |
| Da, BL; Dieterich, D; Kushner, T; Lourdusamy, V; Saberi, B | 1 |
| Chen, DS; Chen, PJ; Kao, JH; Liu, CH; Liu, CJ; Su, TH | 1 |
| Batskikh, SN; Burnevich, EZ; Chulanov, VP; Gusev, DA; Kizlo, SN; Klimova, EA; Krasavina, EN; Mamonova, NA; Samsonov, MY; Tarkhova, EP; Yushchuk, ND; Znoyko, OO | 1 |
| Rodriguez-Reyes, M; Ruiz-Boy, S; Sotoca-Momblona, JM | 1 |
| Ahlenstiel, G; Bowden, S; Dore, GJ; Douglas, M; Doyle, J; Farrell, G; Fisher, L; George, J; Haque, M; Hazeldine, S; Hellard, M; Levy, M; MacQuillan, G; McGarity, B; New, K; O'Beirne, J; O'Keefe, J; Papaluca, T; Prewett, E; Roberts, SK; Sawhney, R; Sievert, W; Sinclair, M; Sood, S; Stoove, M; Strasser, SI; Stuart, KA; Thomas, J; Thompson, AJ; Tse, E; Valaydon, Z; Valiozis, I; Wade, AJ; Weltman, M; Wigg, A; Wilson, M; Woodward, A | 1 |
| Cornberg, M; Deterding, K; Jung, MC; Klinker, H; Manns, MP; Sarrazin, C; Schulze Zur Wiesch, J; Serfert, Y; Simon, KG; Stoehr, A; Teuber, G; Vermehren, J; Wedemeyer, H; Zeuzem, S | 1 |
| Berg, T; Heyne, R; John, C; Klinker, H; Naumann, U; Niederau, C; Serfert, Y; Stein, K; Stoehr, A; Teuber, G; Wiegand, J; Zeuzem, S | 1 |
| Abd-Elsalam, S; Abo-Amer, YE; Ahmed, R; Badawi, R; El-Abgeegy, M; Elguindy, AMA; Elkadeem, M; Elsergany, HF; Elshweikh, SA; Hawash, N; Mansour, L; Mohmed, AA; Soliman, MY; Soliman, S | 1 |
| Buonomo, AR; Cattaneo, L; Coppola, C; Coppola, N; De Pascalis, S; Gentile, I; Martini, S; Mercinelli, S; Messina, V; Nerilli, M; Pinchera, B; Scotto, R; Staiano, L; Stanzione, M; Stornaiuolo, G | 1 |
| Booth, J; Borgia, SM; Conway, B; Cooper, C; Feld, JJ; Lee, S; Lilly, LB; Morales, H; Onofrio, FQ; Ramji, A; Sattar, I; Vachon, ML; Wong, A | 1 |
| Buti, M; Campos, C; Cañizares, A; Carrión, JA; Castro-Iglesias, A; Costa, JG; Esteban, JI; Garcia-Cehic, D; Gregori, J; Macenlle, R; Pamplona, J; Quer, J; Rando, A; Rodriguez-Frias, F; Tabernero, D | 1 |
| Enomoto, M; Fujii, H; Hai, H; Kawada, N; Kozuka, R; Nonomura, A; Tamori, A; Uchida-Kobayashi, S | 1 |
| Begum, F; Ray, U; Srivastava, AK | 1 |
| Flamm, SL; Martin, MT; Patel, S | 1 |
| Beier, C; Cornberg, M; Kordecki, N; Maasoumy, B; Ohlendorf, V; Sandmann, L; Tergast, TL; Wedemeyer, H | 1 |
| Chang, YL; Chou, YC; Hsu, CC; Huang, YH; Huang, YY; Loong, CC; Wu, TH | 1 |
| Bansal, S; Giacomet, V; Hsueh, CH; Indolfi, G; Iorio, R; Kelly, D; Kersey, K; Mangia, A; Mania, A; Nebbia, G; Parhy, B; Pawlowska, M; Sang Yue, M; Shao, J; Szenborn, L | 1 |
| Camus, G; Grant, PM; Gupta, N; Kabihizi, J; Kateera, F; Makuza, JD; Manirambona, L; Mukabatsinda, C; Murangwa, A; Musabeyezu, E; Muvunyi, CM; Nsanzimana, S; Serumondo, J; Shumbusho, F | 1 |
| Öksüz, Z; Serin, MS; Sezgin, O; Temel, GÖ; Üçbilek, E; Yaraş, S | 1 |
| Chen, JJ; Cheng, PN; Chien, SC; Chiu, HC; Chiu, YC; Lee, PL; Tung, HD | 1 |
| Ar, C; Bozcan, S; Canbakan, B; Gültürk, İ; Hatemi, İ; Özdemir, S; Sonsuz, A; Yıldırım, S | 1 |
| Hui, VK; Kao, JH; Kumar, R; Liu, CH; Tan, J; Tan, SS; Thurairajah, PH; Wong, GH; Wong, YJ | 1 |
| Bacinschi, X; Gales, L; Haineala, B; Iliescu, L; Mercan, A; Popescu, GC; Rodica, A; Serban, D; Toma, L; Zgura, A | 1 |
| Falade-Nwulia, O; Karimi-Sari, H; Lim, JK; Rezaee-Zavareh, MS | 1 |
| Allen, R; Alugubelli, YR; Blankenship, LR; Cho, CC; Geng, ZZ; Ji, H; Khatua, K; Li, P; Liu, WR; Ma, XR; Ma, Y; Sankaran, B; Shaabani, N; Vatansever, EC; Xiao, J; Xu, S; Yang, KS; Yu, G | 1 |
55 review(s) available for carbamates and proline
| Article | Year |
|---|---|
Aminoacidurias due to inherited disorders of metabolism. 2.
Topics: Acidosis; Alanine; Amino Acid Metabolism, Inborn Errors; Arginase; Arginine; Carbamates; Citrulline; Dipeptides; Glutarates; Glycine; Histidine; Humans; Hydroxyproline; Hyperglycemia; Infant, Newborn; Keto Acids; Lysine; Malonates; Maple Syrup Urine Disease; Ornithine Carbamoyltransferase; Phosphotransferases; Proline; Sarcosine; Succinates; Urea; Valine | 1973 |
NS5A inhibitors in the treatment of hepatitis C.
Topics: Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Proline; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2013 |
Treating HCV in HIV 2013: on the cusp of change.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Coinfection; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; HIV Infections; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Sofosbuvir; Thiazoles; Treatment Outcome; Uridine Monophosphate; Valine | 2014 |
HCV direct-acting antiviral agents: the best interferon-free combinations.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials as Topic; Disease Eradication; Drug Discovery; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon-alpha; Isoquinolines; Leucine; Oligopeptides; Polyethylene Glycols; Proline; Protease Inhibitors; Pyrrolidines; Quinolines; Recombinant Proteins; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine; Viral Nonstructural Proteins; Virus Replication | 2014 |
Interferon-free therapies for chronic hepatitis C: toward a hepatitis C virus-free world?
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzofurans; Carbamates; Clinical Trials as Topic; Cyclopropanes; Disease Eradication; Drug Combinations; Hepacivirus; Hepatitis C; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
Ombitasvir: a potent pan-genotypic inhibitor of NS5A for the treatment of hepatitis C virus infection.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials as Topic; Drug Evaluation, Preclinical; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Proline; RNA, Viral; Valine; Viral Nonstructural Proteins | 2014 |
Ombitasvir (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Proline; Ribavirin; Valine; Viral Nonstructural Proteins | 2014 |
Hepatitis C management in post-transplant patients.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Drug Therapy, Combination; Fluorenes; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferon alpha-2; Interferon-alpha; Liver Cirrhosis; Liver Transplantation; Oligopeptides; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Recurrence; Ribavirin; Risk Factors; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uridine Monophosphate; Valine; Viral Load | 2015 |
[All-oral, interferon-free therapies for patients with chronic genotype 1 hepatitis C virus infection].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Approval; Drug Combinations; Fluorenes; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Liver Cirrhosis; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2014 |
ABT-450: a novel agent for the treatment of CHC genotype 1: focus on treatment-experienced patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Proline; Protease Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine | 2015 |
A 4-drug combination (Viekira Pak) for hepatitis C.
Topics: 2-Naphthylamine; Anilides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Ombitasvir/paritaprevir/ritonavir and dasabuvir tablets for hepatitis C virus genotype 1 infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Tablets; Uracil; Valine | 2015 |
ABT-450/ ritonavir and ABT-267 in combination with ABT-333 for the treatment of hepatitis C virus.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Uracil; Valine | 2015 |
Management of post transplant hepatitis C in the direct antiviral agents era.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Liver Transplantation; Oligopeptides; Postoperative Complications; Proline; Protease Inhibitors; Pyrrolidines; Recurrence; Ribavirin; Simeprevir; Sofosbuvir; Valine; Viral Nonstructural Proteins | 2015 |
Interferon-free antiviral treatment of chronic hepatitis C in the transplant setting.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cholestasis, Intrahepatic; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Fibrosis; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2015 |
[New era in the treatment of chronic hepatitis C - novel direct acting antivirals].
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Nucleic Acid Synthesis Inhibitors; Proline; Protease Inhibitors; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine; Viral Load; Viral Nonstructural Proteins; Virus Replication | 2015 |
Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir: A Review in Chronic HCV Genotype 1 Infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Working together to tackle HCV infection: ombitasvir/paritaprevir/ritonavir and dasabuvir combination.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Molecular Structure; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2015 |
Management of direct-acting antiviral agent failures.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Failure; Uracil; Uridine Monophosphate; Valine | 2015 |
Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Valine | 2016 |
Ideal oral combinations to eradicate HCV: The role of ribavirin.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Valine | 2016 |
Technivie for HCV genotype 4 infection.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Randomized Controlled Trials as Topic; Ritonavir; Sulfonamides; Valine | 2015 |
Profile of paritaprevir/ritonavir/ombitasvir plus dasabuvir in the treatment of chronic hepatitis C virus genotype 1 infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carrier Proteins; Cyclopropanes; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Macrocyclic Compounds; Molecular Targeted Therapy; Proline; Protease Inhibitors; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Nonstructural Proteins | 2015 |
[Possibilities of IFN-free therapy of hepatitis C].
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Direct-acting antivirals for the treatment of hepatitis C virus infection: optimizing current IFN-free treatment and future perspectives.
Topics: 2-Naphthylamine; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2016 |
Virological and Clinical Response to Interferon-Free Regimens in Patients with HCV-Related Mixed Cryoglobulinemia: Preliminary Results of a Prospective Pilot Study.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Pilot Projects; Proline; Prospective Studies; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Valine | 2017 |
Effects of Mild and Moderate Renal Impairment on Ombitasvir, Paritaprevir, Ritonavir, Dasabuvir, and Ribavirin Pharmacokinetics in Patients with Chronic HCV Infection.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Area Under Curve; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Function Tests; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Renal Insufficiency; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
[Latest Treatment of Viral Hepatitis--Overcoming Hepatitis C and Reactivation of Hepatitis B].
Topics: Anilides; Antineoplastic Agents; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; DNA, Viral; Drug Therapy, Combination; Hepatitis B; Hepatitis B Surface Antigens; Hepatitis B Vaccines; Hepatitis B virus; Hepatitis C; Humans; Imidazoles; Immunoassay; Immunosuppressive Agents; Interferons; Interleukins; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Pyrrolidines; Ritonavir; Rituximab; Sensitivity and Specificity; Sulfonamides; Transfusion Reaction; Valine; Virus Activation | 2016 |
Ombitasvir/Paritaprevir/Ritonavir: A Review in Chronic HCV Genotype 4 Infection.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Valine | 2016 |
Hepatitis C treatment from "response-guided" to "resource-guided" therapy in the transition era from interferon-containing to interferon-free regimens.
Topics: Antiviral Agents; Carbamates; Drug Administration Schedule; Drug Therapy, Combination; Hepatitis C; Humans; Imidazoles; Interferons; Isoquinolines; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Time Factors; Valine; Viral Load | 2017 |
HCV management in resource-constrained countries.
Topics: Aminoisobutyric Acids; Antiviral Agents; Australia; Benzimidazoles; Carbamates; Continuity of Patient Care; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Drugs, Generic; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Risk Factors; Sofosbuvir; Sulfonamides; Valine | 2017 |
Clinical Pharmacokinetics of Ombitasvir.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Drug Interactions; Drug Therapy, Combination; Food-Drug Interactions; Hepacivirus; Hepatitis C, Chronic; Humans; Proline; Valine | 2017 |
Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir: Drug Interactions With Antiretroviral Agents and Drugs forSubstance Abuse.
Topics: 2-Naphthylamine; Anilides; Anti-Retroviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Protease Inhibitors; Ritonavir; Substance-Related Disorders; Sulfonamides; Uracil; Valine | 2017 |
Ombitasvir and paritaprevir boosted with ritonavir and combined with dasabuvir for chronic hepatitis C.
Topics: 2-Naphthylamine; Administration, Oral; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2017 |
Real-world effectiveness of ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in patients with hepatitis C virus genotype 1 or 4 infection: A meta-analysis.
Topics: Anilides; Antiviral Agents; Carbamates; Comorbidity; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Viral Load | 2017 |
Safety of the 2D/3D direct-acting antiviral regimen in HCV-induced Child-Pugh A cirrhosis - A pooled analysis.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2017 |
Sofosbuvir, velpatasvir and voxilaprevir combination for the treatment of hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2017 |
Evaluation of sofosbuvir, velpatasvir plus voxilaprevir as fixed-dose co-formulation for treating hepatitis C.
Topics: Aminoisobutyric Acids; Animals; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Interactions; Drug Resistance, Viral; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Tablets; Treatment Outcome | 2017 |
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with or without Ribavirin for Treatment of Hepatitis C Virus Genotype 1: A Systematic Review and Meta-analysis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2017 |
Citius, Altius, Fortius: The New Paradigm in the Treatment of Chronic Hepatitis C Disease.
Topics: Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Mutation; Proline; Sulfonamides; Valine | 2018 |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Pan-Genotypic Direct-Acting Antiviral Combination for Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Micro-costing analysis of guideline-based treatment by direct-acting agents: the real-life case of hepatitis C management in Brazil.
Topics: Antiviral Agents; Brazil; Carbamates; Costs and Cost Analysis; Drug Costs; Genotype; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Liver Cirrhosis; Oligopeptides; Proline; Pyrrolidines; Ribavirin; Simeprevir; Sofosbuvir; Valine | 2017 |
Cutaneous eruptions by new therapies against hepatitis C virus infection. Not as common as we presumed.
Topics: 2-Naphthylamine; Adrenal Cortex Hormones; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Eruptions; Drug Therapy, Combination; Female; Follow-Up Studies; Hepacivirus; Hepatitis C; Histamine Antagonists; Humans; Incidence; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Sustained Virological Response in Special Populations with Chronic Hepatitis C Using Interferon-Free Treatments: A Systematic Review and Meta-analysis of Observational Cohort Studies.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
Sofosbuvir/Velpatasvir/Voxilaprevir: A Review in Chronic Hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Drug Resistance, Viral; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
Sofosbuvir, velpatasvir and voxilaprevir combination therapy for treating patients with hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome | 2018 |
Sofosbuvir/velpatasvir/voxilaprevir: a highly effective option for retreatment of hepatitis C in difficult-to-treat patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2019 |
Review article: novel antivirals for hepatitis C-sofosbuvir/velpatasvir/voxilaprevir, glecaprevir/pibrentasvir.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Expert opinion on the management of renal manifestations of chronic HCV infection.
Topics: 2-Naphthylamine; Amides; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Disease Management; Drug Therapy, Combination; Expert Testimony; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Practice Guidelines as Topic; Proline; Pyrrolidines; Quinoxalines; Renal Insufficiency, Chronic; Risk Factors; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Treatment of hepatitis C virus genotype 4 in the DAA era.
Topics: Aminoisobutyric Acids; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interferons; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
[Advances in combination therapy of ombitasvir and dasabuvir for chronic hepatitis C virus genotype 1 infection].
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Proline; Sulfonamides; United States; Uracil; Valine | 2018 |
Evolutionary Pathways to Persistence of Highly Fit and Resistant Hepatitis C Virus Protease Inhibitor Escape Variants.
Topics: 2-Naphthylamine; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Denmark; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Male; Prognosis; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Sulfonamides; Uracil; Valine | 2019 |
Upcoming direct acting antivirals for hepatitis C patients with a prior treatment failure.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure | 2019 |
New approaches in viraemic organ transplantation and antiviral therapies.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Guanine; Hepatitis B, Chronic; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Proline; Quinoxalines; Salvage Therapy; Sofosbuvir; Sulfonamides; Tenofovir; Transplants | 2020 |
Progress Toward Hepatitis C Virus Elimination: Therapy and Implementation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzofurans; Carbamates; Drug Therapy, Combination; Global Health; Health Care Costs; Hepatitis C, Chronic; Humans; Imidazoles; Proline; Pyrrolidines; Sofosbuvir; Sulfonamides; Uracil; Valine; World Health Organization | 2020 |
78 trial(s) available for carbamates and proline
| Article | Year |
|---|---|
Phase 2b trial of interferon-free therapy for hepatitis C virus genotype 1.
Topics: Administration, Oral; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; RNA, Viral; Sulfonamides; Valine; Viral Nonstructural Proteins; Young Adult | 2014 |
Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retreatment; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Load; Young Adult | 2014 |
Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Viral Load; Young Adult | 2014 |
ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ribavirin; Sulfonamides; Valine | 2014 |
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Topics: Adolescent; Adult; Aged; Amides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Interferon alpha-2; Interferon-alpha; Male; Middle Aged; Polyethylene Glycols; Proline; Quinoxalines; Recombinant Proteins; Ribavirin; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; Young Adult | 2014 |
ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hemoglobins; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ribavirin; RNA, Viral; Sulfonamides; Valine | 2014 |
ABT-450, ritonavir, ombitasvir, and dasabuvir achieves 97% and 100% sustained virologic response with or without ribavirin in treatment-experienced patients with HCV genotype 1b infection.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Europe; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Puerto Rico; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Time Factors; Treatment Outcome; United States; Uracil; Valine; Viral Load | 2014 |
Exploratory trial of ombitasvir and ABT-450/r with or without ribavirin for HCV genotype 1, 2, and 3 infection.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Sulfonamides; Treatment Outcome; Valine; Viral Load | 2015 |
An interferon-free antiviral regimen for HCV after liver transplantation.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins; Young Adult | 2014 |
Randomized trial of interferon- and ribavirin-free ombitasvir/paritaprevir/ritonavir in treatment-experienced hepatitis C virus-infected patients.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine; Young Adult | 2015 |
Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvir.
Topics: 2-Naphthylamine; Administration, Oral; Adolescent; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C Antibodies; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2015 |
Pharmacokinetics and dose recommendations for cyclosporine and tacrolimus when coadministered with ABT-450, ombitasvir, and dasabuvir.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Area Under Curve; Carbamates; Cyclopropanes; Cyclosporine; Drug Administration Schedule; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Sulfonamides; Tacrolimus; Uracil; Valine; Young Adult | 2015 |
Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial.
Topics: Adolescent; Adult; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2015 |
Ombitasvir/paritaprevir/r and dasabuvir plus ribavirin in HCV genotype 1-infected patients on methadone or buprenorphine.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Analgesics, Opioid; Anilides; Antiviral Agents; Buprenorphine; Carbamates; Cyclopropanes; DNA, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Methadone; Middle Aged; Opioid-Related Disorders; Proline; Retrospective Studies; Ribavirin; Sulfonamides; Uracil; Valine; Young Adult | 2015 |
Pharmacokinetics and safety of co-administered paritaprevir plus ritonavir, ombitasvir, and dasabuvir in hepatic impairment.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepatic Insufficiency; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2015 |
Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis.
Topics: Aged; Anilides; Antiviral Agents; Asian People; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Valine | 2015 |
Efficacy and Safety of Ombitasvir, Paritaprevir, and Ritonavir in an Open-Label Study of Patients With Genotype 1b Chronic Hepatitis C Virus Infection With and Without Cirrhosis.
Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Carbamates; Carrier Proteins; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Enzyme Inhibitors; Europe; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Intracellular Signaling Peptides and Proteins; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Remission Induction; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; United States; Valine; Viral Nonstructural Proteins | 2015 |
Ombitasvir/paritaprevir/r, dasabuvir and ribavirin for cirrhotic HCV patients with thrombocytopaenia and hypoalbuminaemia.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hypertension, Portal; Hypoalbuminemia; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Sulfonamides; Thrombocytopenia; Treatment Outcome; Uracil; Valine; Young Adult | 2015 |
Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir.
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Phylogeny; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Valine; Young Adult | 2015 |
Efficacy and safety of ombitasvir/paritaprevir/r and dasabuvir compared to IFN-containing regimens in genotype 1 HCV patients: The MALACHITE-I/II trials.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferon alpha-2; Interferon-alpha; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polyethylene Glycols; Proline; Recombinant Proteins; Sulfonamides; Uracil; Valine | 2016 |
Serum miR-122 may serve as a biomarker for response to direct acting antivirals: effect of paritaprevir/R with dasabuvir or ombitasvir on miR-122 in HCV-infected subjects.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; MicroRNAs; Proline; Sulfonamides; Uracil; Valine; Virus Replication | 2016 |
Drug Interactions with the Direct-Acting Antiviral Combination of Ombitasvir and Paritaprevir-Ritonavir.
Topics: Adult; Anilides; Antacids; Anti-Arrhythmia Agents; Anticoagulants; Antidepressive Agents; Antifungal Agents; Antiviral Agents; Area Under Curve; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Narcotic Antagonists; Proline; Ritonavir; Sulfonamides; Valine | 2016 |
Sustained virologic response of 100% in HCV genotype 1b patients with cirrhosis receiving ombitasvir/paritaprevir/r and dasabuvir for 12weeks.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2016 |
Drug-Drug Interactions between Sofosbuvir and Ombitasvir-Paritaprevir-Ritonavir with or without Dasabuvir.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2016 |
Analysis of Hepatitis C Virus Genotype 1b Resistance Variants in Japanese Patients Treated with Paritaprevir-Ritonavir and Ombitasvir.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genetics, Population; Hepacivirus; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Polymorphism, Genetic; Proline; Ritonavir; Sulfonamides; Treatment Failure; Valine; Viral Nonstructural Proteins | 2016 |
Evaluation of Drug-Drug Interactions Between Hepatitis C Antiviral Agents Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and HIV-1 Protease Inhibitors.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; HIV Infections; HIV Protease Inhibitors; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2016 |
Drug-Drug Interactions Between the Anti-Hepatitis C Virus 3D Regimen of Ombitasvir, Paritaprevir/Ritonavir, and Dasabuvir and Eight Commonly Used Medications in Healthy Volunteers.
Topics: 2-Naphthylamine; Adolescent; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Healthy Volunteers; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Pharmacokinetics; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2016 |
Efficacy of Direct-Acting Antiviral Combination for Patients With Hepatitis C Virus Genotype 1 Infection and Severe Renal Impairment or End-Stage Renal Disease.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2016 |
Exposure-Response Relationship for Ombitasvir and Paritaprevir/Ritonavir in Hepatitis C Virus Subgenotype 1b-Infected Japanese Patients in the Phase 3 Randomized GIFT-I Study.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Monitoring; Drug Therapy, Combination; Female; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Valine | 2016 |
Exposure-Efficacy Analyses of Ombitasvir, Paritaprevir/Ritonavir with Dasabuvir ± Ribavirin in HCV Genotype 1-Infected Patients.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine; Young Adult | 2016 |
Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; New Zealand; Proline; Protease Inhibitors; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Viral Nonstructural Proteins; Young Adult | 2016 |
Pharmacokinetics of Tacrolimus and Cyclosporine in Liver Transplant Recipients Receiving 3 Direct-Acting Antivirals as Treatment for Hepatitis C Infection.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Dosage Calculations; Drug Therapy, Combination; Female; Hepatitis C; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Ritonavir; Sulfonamides; Tacrolimus; Uracil; Valine; Young Adult | 2016 |
Drug-Drug Interaction of Omeprazole With the HCV Direct-Acting Antiviral Agents Paritaprevir/Ritonavir and Ombitasvir With and Without Dasabuvir.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-Ulcer Agents; Antiviral Agents; Area Under Curve; Carbamates; Cyclopropanes; Cytochrome P-450 CYP2C19; Drug Interactions; Drug Therapy, Combination; Female; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Omeprazole; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Population Pharmacokinetics of Paritaprevir, Ombitasvir, and Ritonavir in Japanese Patients with Hepatitis C Virus Genotype 1b Infection.
Topics: Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Double-Blind Method; Drug Therapy, Combination; Female; Fibrosis; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Metabolic Clearance Rate; Middle Aged; Models, Biological; Proline; Renal Insufficiency; Ritonavir; Sex Factors; Sulfonamides; Valine; Young Adult | 2017 |
Pharmacokinetics and Tolerability of Anti-Hepatitis C Virus Treatment with Ombitasvir, Paritaprevir, Ritonavir, with or Without Dasabuvir, in Subjects with Renal Impairment.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Diseases; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Hepatitis C Virus Genotype 2, 3, 4, or 6 Infections in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Ribavirin; Serine Proteases; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Nonstructural Proteins; Young Adult | 2016 |
Drug-Drug Interaction between the Direct-Acting Antiviral Regimen of Ombitasvir-Paritaprevir-Ritonavir plus Dasabuvir and the HIV Antiretroviral Agent Dolutegravir or Abacavir plus Lamivudine.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Anti-Retroviral Agents; Carbamates; Cyclopropanes; Dideoxynucleosides; Drug Combinations; Drug Interactions; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; HIV Infections; Humans; Lactams, Macrocyclic; Lamivudine; Macrocyclic Compounds; Male; Middle Aged; Oxazines; Piperazines; Proline; Pyridones; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Real-world effectiveness and safety of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C: AMBER study.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Diarrhea; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2016 |
Sofosbuvir-velpatasvir-voxilaprevir with or without ribavirin in direct-acting antiviral-experienced patients with genotype 1 hepatitis C virus.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Confidence Intervals; Cyclopropanes; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Ribavirin; Severity of Illness Index; Sofosbuvir; Sulfonamides; Treatment Outcome; Young Adult | 2017 |
TURQUOISE-I Part 1b: Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with Ribavirin for Hepatitis C Virus Infection in HIV-1 Coinfected Patients on Darunavir.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Anti-Retroviral Agents; Body Mass Index; Carbamates; CD4 Lymphocyte Count; Coinfection; Cyclopropanes; Darunavir; Dose-Response Relationship, Drug; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
Efficacy of 8 Weeks of Sofosbuvir, Velpatasvir, and Voxilaprevir in Patients With Chronic HCV Infection: 2 Phase 3 Randomized Trials.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Young Adult | 2017 |
Ombitasvir, paritaprevir, and ritonavir plus ribavirin in adults with hepatitis C virus genotype 4 infection and cirrhosis (AGATE-I): a multicentre, phase 3, randomised open-label trial.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2016 |
Ombitasvir, paritaprevir, and ritonavir plus ribavirin for chronic hepatitis C virus genotype 4 infection in Egyptian patients with or without compensated cirrhosis (AGATE-II): a multicentre, phase 3, partly randomised open-label trial.
Topics: Administration, Oral; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Egypt; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2016 |
Ombitasvir, paritaprevir, and ritonavir plus dasabuvir for 8 weeks in previously untreated patients with hepatitis C virus genotype 1b infection without cirrhosis (GARNET): a single-arm, open-label, phase 3b trial.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polymorphism, Genetic; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uracil; Valine | 2017 |
Randomized Phase 3 Trial of Ombitasvir/Paritaprevir/Ritonavir and Ribavirin for Hepatitis C Virus Genotype 2-Infected Japanese Patients.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2017 |
Sofosbuvir, Velpatasvir, and Voxilaprevir for Previously Treated HCV Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Female; Genotype; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins | 2017 |
Efficacy and safety results of patients with HCV genotype 2 or 3 infection treated with ombitasvir/paritaprevir/ritonavir and sofosbuvir with or without ribavirin (QUARTZ II-III).
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Resistance characterization of hepatitis C virus genotype 2 from Japanese patients treated with ombitasvir and paritaprevir/ritonavir.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polymorphism, Genetic; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Failure; Treatment Outcome; Valine | 2018 |
Efficacy and safety of glecaprevir/pibrentasvir in Japanese patients with chronic genotype 1 hepatitis C virus infection with and without cirrhosis.
Topics: Adult; Age Distribution; Aged; Aged, 80 and over; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2018 |
IFNL4 Genotype Is Associated With Virologic Relapse After 8-Week Treatment With Sofosbuvir, Velpatasvir, and Voxilaprevir.
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Interleukins; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Recurrence; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2017 |
Effect of ombitasvir/paritaprevir/ritonavir + dasabuvir regimen on health-related quality of life for patients with hepatitis C.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Internationality; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quality of Life; Regression Analysis; Ribavirin; Ritonavir; Severity of Illness Index; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Glecaprevir-Pibrentasvir for 8 or 12 Weeks in HCV Genotype 1 or 3 Infection.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Valine; Viral Load | 2018 |
Ribavirin dose management in HCV patients receiving ombitasvir/paritaprevir/ritonavir and dasabuvir with ribavirin.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Internationality; Lactams, Macrocyclic; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir in HIV/HCV-coinfected patients with genotype 1 in real-life practice.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Retreatment Efficacy of Sofosbuvir/Ombitasvir/Paritaprevir/Ritonavir + Ribavirin for Hepatitis C Virus Genotype 4 Patients.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine; Young Adult | 2018 |
Characterization of demographics and NS5A genetic diversity for hepatitis C virus genotype 4-infected patients with or without cirrhosis treated with ombitasvir/paritaprevir/ritonavir.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cluster Analysis; Cyclopropanes; Demography; Europe; Female; Genetic Variation; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Molecular Epidemiology; North America; Phylogeny; Prevalence; Proline; Ritonavir; Sequence Analysis, DNA; Sulfonamides; Treatment Outcome; Valine; Viral Nonstructural Proteins | 2018 |
Shortened therapy of eight weeks with paritaprevir/ritonavir/ombitasvir and dasabuvir is highly effective in people with recent HCV genotype 1 infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Australia; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; England; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Intention to Treat Analysis; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; New Zealand; Proline; Prospective Studies; Ribavirin; Ritonavir; RNA, Viral; Safety; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin for chronic hepatitis C virus genotype 1b-infected cirrhotics (TURQUOISE-IV).
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Republic of Belarus; Ribavirin; Ritonavir; Russia; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine | 2018 |
Deferred treatment with sofosbuvir-velpatasvir-voxilaprevir for patients with chronic hepatitis C virus who were previously treated with an NS5A inhibitor: an open-label substudy of POLARIS-1.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2018 |
Viral eradication is required for sustained improvement of patient-reported outcomes in patients with hepatitis C.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Linear Models; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Change in the hepatic profile of hepatitis C virus genotype 4-infected patients with compensated cirrhosis receiving ombitasvir, paritaprevir, and ritonavir plus ribavirin: A subanalysis of the AGATE-II study.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2018 |
Pharmacokinetics of Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir in Healthy Chinese Subjects and HCV GT1b-Infected Chinese, South Korean and Taiwanese Patients.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Asian People; Carbamates; China; Cyclopropanes; Female; Healthy Volunteers; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Republic of Korea; Ritonavir; Sulfonamides; Taiwan; Uracil; Valine | 2019 |
Outcome and adverse events in patients with chronic hepatitis C treated with direct-acting antivirals: a clinical randomized study.
Topics: 2-Naphthylamine; Adult; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fatigue; Female; Fluorenes; Genotype; Headache; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
No impact of resistance-associated substitutions on the efficacy of sofosbuvir, velpatasvir, and voxilaprevir for 12 weeks in HCV DAA-experienced patients.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome; Viral Nonstructural Proteins | 2018 |
Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir ± Ribavirin for HCV in Brazilian Adults with Advanced Fibrosis.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Brazil; Carbamates; Cyclopropanes; Drug Combinations; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Sofosbuvir/Velpatasvir/Voxilaprevir for patients with HCV who previously received a Sofosbuvir/Velpatasvir-containing regimen: Results from a retreatment study.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
A prospective study of daclatasvir and sofosbuvir in chronic HCV-infected kidney transplant recipients.
Topics: Adult; Aged; Aminoisobutyric Acids; Antiviral Agents; Biopsy, Needle; Calcineurin Inhibitors; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Glucose Intolerance; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Leucine; Liver; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; RNA, Viral; Salvage Therapy; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine; Viral Load; Viral Nonstructural Proteins; Viremia | 2019 |
Ombitasvir/paritaprevir/ritonavir and dasabuvir with or without sofosbuvir for patients with hepatitis C virus genotype 1 infection who failed a prior course of direct-acting antiviral therapy.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
Efficacy and safety of ombitasvir/paritaprevir/ritonavir and dasabuvir with low-dose ribavirin in patients with chronic hepatitis C virus genotype 1a infection without cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2019 |
A pilot study of safety and efficacy of HCV retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with or without HIV (RESOLVE STUDY).
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Pilot Projects; Proline; Quinoxalines; Recurrence; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2019 |
Effectiveness and safety of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C previously treated with DAAs.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Monitoring; Drug Resistance, Viral; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2019 |
Intrahepatic Viral Kinetics During Direct-Acting Antivirals for Hepatitis C in Human Immunodeficiency Virus Coinfection: The AIDS Clinical Trials Group A5335S Substudy.
Topics: 2-Naphthylamine; Acquired Immunodeficiency Syndrome; Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Female; Hepatitis C, Chronic; Humans; Kinetics; Lactams, Macrocyclic; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; United States; Uracil; Valine; Viral Load | 2020 |
Ombitasvir/paritaprevir/ritonavir & dasabuvir ± ribavirin following protease inhibitors failure - a prospective multi-centre trial.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2020 |
High success rates for the use of sofosbuvir/ombitasvir/paritaprevir/ritonavir + ribavirin and sofosbuvir/simeprevir/daclatasvir + ribavirin in retreatment of chronic hepatitis C infection after unsuccessful sofosbuvir/daclatasvir therapy: a real-life exp
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2020 |
Hepatitis C Virus (HCV) Direct-Acting Antiviral Therapy in Persons With Human Immunodeficiency Virus-HCV Genotype 1 Coinfection Resulting in High Rate of Sustained Virologic Response and Variable in Normalization of Soluble Markers of Immune Activation.
Topics: 2-Naphthylamine; Adult; Anilides; Anti-HIV Agents; Antiviral Agents; Biomarkers; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Immunologic Factors; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2020 |
[Efficacy and safety of narlaprevir/ritonavir and daclatasvir non interferon combination in population of Russian patients with chronic hepatitis C].
Topics: Adult; Antiviral Agents; Carbamates; Cyclopropanes; Dipeptides; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Leucine; Middle Aged; Proline; Pyrrolidines; Ritonavir; Russia; Sulfones; Treatment Outcome; Urea; Valine | 2019 |
Safety and efficacy of sofosbuvir-velpatasvir-voxilaprevir for re-treatment of chronic hepatitis C virus infection in patients with previous direct-acting antiviral treatment failure in Rwanda (SHARED-3): a single-arm trial.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Death, Sudden; Female; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Rwanda; Sofosbuvir; Sulfonamides; Treatment Failure | 2022 |
212 other study(ies) available for carbamates and proline
| Article | Year |
|---|---|
Microtubules and axoplasmic transport.
Topics: Animals; Axonal Transport; Carbamates; Colchicine; Dose-Response Relationship, Drug; Microtubules; Nerve Tissue Proteins; Optic Nerve; Podophyllotoxin; Proline; Rats; Tritium; Vinblastine | 1974 |
Ureidosuccinic acid uptake in yeast and some aspects of its regulation.
Topics: Amino Acids; Ammonium Sulfate; Aspartic Acid; Canavanine; Carbamates; Carbon Isotopes; Citrulline; Culture Media; Drug Resistance, Microbial; Genetic Complementation Test; Genetics, Microbial; Membrane Transport Proteins; Mutation; Phenotype; Proline; Pyrimidines; Saccharomyces; Saccharomyces cerevisiae | 1972 |
Genetic control of the arginine pathways in Aspergillus nidulans. Common regulation of anabolism and catabolism.
Topics: Arginase; Arginine; Aspartate Carbamoyltransferase; Aspartic Acid; Aspergillus; Aspergillus nidulans; Carbamates; Enzyme Repression; Genes, Regulator; Keto Acids; Mutation; Ornithine; Phosphates; Proline; Transaminases | 1972 |
Effects of mebendazole on the absorption of low molecular weight nutrients by Ascaris suum.
Topics: Animals; Anthelmintics; Ascaris; Benzimidazoles; Benzoates; Carbamates; Carbon Isotopes; Culture Media; Female; Fructose; Glucose; Glycine; Glycogen; Intestine, Small; Methionine; Molecular Weight; Palmitic Acids; Proline | 1973 |
Pantetheine-linked peptide intermediates in gramicidin S and tyrocidine biosynthesis.
Topics: Asparagine; Carbamates; Carbon Isotopes; Chromatography, Gel; Chromatography, Thin Layer; Enzymes; Hydroxybutyrates; Pepsin A; Peptide Biosynthesis; Peptide Chain Initiation, Translational; Peptides; Phenylalanine; Proline; Sulfhydryl Compounds; Tyrothricin | 1971 |
Metabolism of bovine semen. XX. Role of ammonia in interactions between the citric acid and urea cycles.
Topics: Amino Acids; Ammonia; Animals; Arginase; Arginine; Carbamates; Carbon Dioxide; Carbon Isotopes; Cattle; Cell Fractionation; Citric Acid Cycle; Citrulline; Male; Ornithine; Ornithine Carbamoyltransferase; Oxygen Consumption; Phosphotransferases; Proline; Pyruvates; Rabbits; Semen; Spermatozoa; Urea; Valerates | 1969 |
Chemistry of carbamoyl disulfide protected derivatives of proline.
Topics: Carbamates; Chemical Phenomena; Chemistry; Disulfides; Indicators and Reagents; Proline; Structure-Activity Relationship | 1982 |
In vitro cytotoxicity in rabbit corneal cells of two new local anesthetics--pentacaine and heptacaine.
Topics: Anesthetics, Local; Animals; Carbamates; Cornea; In Vitro Techniques; Piperidines; Proline; Rabbits; Thymidine; Trimecaine | 1981 |
Probing the stereoselectivity of the Heck arylation of endocyclic enecarbamates with diazonium salts. Concise syntheses of (2S,5R)-phenylproline methyl ester and Schramm's C-azanucleoside.
Topics: Antiprotozoal Agents; Carbamates; Cholecystokinin; Diazonium Compounds; Esters; Nucleosides; Proline; Stereoisomerism | 2003 |
ARGININE AS A PRECURSOR OF PYRIMIDINES IN STRAIN L-929 FIBROBLASTS INFECTED WITH PLEUROPNEUMONIA-LIKE ORGANISMS.
Topics: Arginase; Arginine; Aspartic Acid; Carbamates; Carbon Isotopes; Connective Tissue; Fibroblasts; Glutamine; Ligases; Metabolism; Mycoplasma; Ornithine; Ornithine Carbamoyltransferase; Orotic Acid; Phosphates; Phosphotransferases; Proline; Proteins; Pyrimidines; Research; Thymidine; Tissue Culture Techniques; Uracil; Urea; Ureohydrolases | 1964 |
Structure-activity study on a novel series of macrocyclic inhibitors of the hepatitis C virus NS3 protease leading to the discovery of BILN 2061.
Topics: Administration, Oral; Animals; Antiviral Agents; Biological Availability; Carbamates; Hepacivirus; Heterocyclic Compounds; Injections, Intravenous; Proline; Protease Inhibitors; Rats; Structure-Activity Relationship; Viral Nonstructural Proteins | 2004 |
Endothelin-converting enzyme-1 inhibition and growth of human glioblastoma cells.
Topics: Antineoplastic Agents; Aspartic Acid Endopeptidases; Carbamates; Cell Line, Tumor; Cell Proliferation; Central Nervous System Neoplasms; Drug Screening Assays, Antitumor; Endothelin-1; Endothelin-Converting Enzymes; Glioblastoma; Humans; Hydrazines; Metalloendopeptidases; Proline; Pyrimidines; Pyrrolidines; Structure-Activity Relationship; Sulfhydryl Compounds | 2005 |
Naturally occurring NS3-protease-inhibitor resistant mutant A156T in the liver of an untreated chronic hepatitis C patient.
Topics: Adult; Amino Acid Sequence; Base Sequence; Carbamates; DNA, Viral; Drug Resistance, Viral; Genes, Viral; Hepacivirus; Hepatitis C, Chronic; Humans; Liver; Macrocyclic Compounds; Male; Molecular Sequence Data; Oligopeptides; Point Mutation; Proline; Quinolines; Sequence Homology, Amino Acid; Sequence Homology, Nucleic Acid; Serine Endopeptidases; Serine Proteinase Inhibitors; Thiazoles; Viral Nonstructural Proteins | 2008 |
Diphenylprolinol silyl ether as a catalyst in an enantioselective, catalytic, formal aza [3+3] cycloaddition reaction for the formation of enantioenriched piperidines.
Topics: Aldehydes; Aza Compounds; Carbamates; Catalysis; Cyclization; Ethers; Molecular Structure; Piperidines; Proline; Stereoisomerism | 2008 |
Mapping natural polymorphisms of hepatitis C virus NS3/4A protease and antiviral resistance to inhibitors in worldwide isolates.
Topics: Amino Acid Sequence; Antiviral Agents; Carbamates; Carrier Proteins; Drug Resistance, Viral; Global Health; Hepacivirus; Hepatitis C; Humans; Intracellular Signaling Peptides and Proteins; Macrocyclic Compounds; Microbial Sensitivity Tests; Molecular Sequence Data; Oligopeptides; Polymorphism, Genetic; Proline; Protease Inhibitors; Quinolines; Sequence Alignment; Thiazoles; Viral Nonstructural Proteins; Viral Proteins | 2008 |
Discovery of novel, potent and bioavailable proline-urea based macrocyclic HCV NS3/4A protease inhibitors.
Topics: Administration, Oral; Animals; Antiviral Agents; Carbamates; Combinatorial Chemistry Techniques; Drug Design; Hepacivirus; Male; Models, Molecular; Molecular Structure; Proline; Rats; Rats, Sprague-Dawley; Serine Proteinase Inhibitors; Structure-Activity Relationship; Urea; Viral Nonstructural Proteins | 2008 |
Naturally occurring dominant resistance mutations to hepatitis C virus protease and polymerase inhibitors in treatment-naïve patients.
Topics: Antiviral Agents; Carbamates; Cohort Studies; Drug Resistance, Viral; Female; Genetic Testing; Hepacivirus; Hepatitis C; Humans; Macrocyclic Compounds; Male; Mutation; Oligopeptides; Phenylthiourea; Phylogeny; Proline; Protease Inhibitors; Quinolines; Thiazoles; Viral Load; Viral Nonstructural Proteins | 2008 |
HCV-NS3 inhibitors: determination of their kinetic parameters and mechanism.
Topics: Amino Acid Substitution; Antiviral Agents; Carbamates; Drug Resistance, Viral; Genotype; Half-Life; Hepacivirus; Humans; Kinetics; Macrocyclic Compounds; Models, Biological; Mutation; Oligopeptides; Proline; Quinolines; Recombinant Proteins; Serine Endopeptidases; Serine Proteinase Inhibitors; Thiazoles; Viral Nonstructural Proteins | 2009 |
Estimation of inhibitory quotient using a comparative equilibrium dialysis assay for prediction of viral response to hepatitis C virus inhibitors.
Topics: Antiviral Agents; Blood Proteins; Carbamates; Cell Line; Comparative Effectiveness Research; Dialysis; Hepacivirus; Hepatitis C; Humans; Inhibitory Concentration 50; Macrocyclic Compounds; Membranes, Artificial; Oligopeptides; Phenylthiourea; Plasma; Proline; Protease Inhibitors; Protein Binding; Quinolines; RNA, Viral; Thiazoles; Viral Load | 2011 |
Discovery of potent hepatitis C virus NS5A inhibitors with dimeric structures.
Topics: Alanine; Antiviral Agents; Carbamates; Cell Line; Chromatography, High Pressure Liquid; Diarrhea Viruses, Bovine Viral; Drug Discovery; Drug Resistance, Viral; Hepacivirus; Humans; Imidazoles; Mass Spectrometry; Nuclear Magnetic Resonance, Biomolecular; Proline; Pyrrolidines; Stilbenes; Thiazolidines; Valine; Viral Nonstructural Proteins; Virus Replication | 2011 |
Proline-based chiral stationary phases: a molecular dynamics study of the interfacial structure.
Topics: 2-Propanol; Carbamates; Chromatography, High Pressure Liquid; Chromatography, Reverse-Phase; Hexanes; Hydrogen Bonding; Methanol; Molecular Dynamics Simulation; Proline; Stereoisomerism; Thermodynamics; Water | 2011 |
Annual drug update: 2011 in review.
Topics: Abatacept; Aminoglycosides; Carbamates; Drug Approval; Fentanyl; Fidaxomicin; Humans; Immunoconjugates; Indans; Linagliptin; Phenylenediamines; Proline; Purines; Quinazolines; Quinolones; United States; United States Food and Drug Administration | 2012 |
(S)-(-)-N-(pentafluorobenzylcarbamoyl)prolyl chloride: a chiral derivatisation reagent designed for gas chromatography/negative ion chemical ionisation mass spectrometry of amino compounds.
Topics: Amphetamine; Caprylates; Carbamates; Central Nervous System Stimulants; Gas Chromatography-Mass Spectrometry; Indicators and Reagents; Ions; Methylphenidate; Proline; Stereoisomerism | 2012 |
HCV NS5A replication complex inhibitors. Part 2: investigation of stilbene prolinamides.
Topics: Antiviral Agents; Carbamates; Dose-Response Relationship, Drug; Imidazoles; Molecular Structure; Proline; Pyrrolidines; Stilbenes; Structure-Activity Relationship; Valine; Viral Nonstructural Proteins; Virus Replication | 2012 |
HCV NS5A replication complex inhibitors. Part 3: discovery of potent analogs with distinct core topologies.
Topics: Antiviral Agents; Carbamates; Hepacivirus; Imidazoles; Inhibitory Concentration 50; Molecular Structure; Proline; Pyrrolidines; Structure-Activity Relationship; Valine; Viral Nonstructural Proteins; Virus Replication | 2013 |
Computational study on the drug resistance mechanism against HCV NS3/4A protease inhibitors vaniprevir and MK-5172 by the combination use of molecular dynamics simulation, residue interaction network, and substrate envelope analysis.
Topics: Amides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Hepacivirus; Indoles; Isoindoles; Lactams, Macrocyclic; Leucine; Molecular Dynamics Simulation; Mutation; Proline; Protease Inhibitors; Protein Conformation; Quinoxalines; Sulfonamides; Thermodynamics; Viral Nonstructural Proteins | 2014 |
Differential sensitivity of 5'UTR-NS5A recombinants of hepatitis C virus genotypes 1-6 to protease and NS5A inhibitors.
Topics: Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Carrier Proteins; Cell Line, Tumor; Genotype; Hepacivirus; Humans; Imidazoles; Intracellular Signaling Peptides and Proteins; Liver; Liver Neoplasms; Mutation; Oligopeptides; Proline; Protease Inhibitors; Pyrrolidines; Valine; Viral Nonstructural Proteins | 2014 |
Minimum costs for producing hepatitis C direct-acting antivirals for use in large-scale treatment access programs in developing countries.
Topics: Aminoisobutyric Acids; Anti-HIV Agents; Antiviral Agents; Carbamates; Developing Countries; Drug Industry; Drug Therapy, Combination; Health Services Accessibility; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Leucine; Oligopeptides; Proline; Pyrrolidines; Quinolines; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Thiazoles; Uridine Monophosphate; Valine | 2014 |
Discovery of ABT-267, a pan-genotypic inhibitor of HCV NS5A.
Topics: 2-Naphthylamine; Anilides; Animals; Antiviral Agents; Biological Availability; Carbamates; Cell Line; Drug Discovery; Genotype; Hepacivirus; Humans; Proline; Rats; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2014 |
Accounting for strain variations and resistance mutations in the characterization of hepatitis C NS3 protease inhibitors.
Topics: Antiviral Agents; Carbamates; Cloning, Molecular; Cyclopropanes; Drug Resistance, Viral; Escherichia coli; Gene Expression; Genetic Variation; Genotype; Hepacivirus; Isoindoles; Lactams; Lactams, Macrocyclic; Macrocyclic Compounds; Mutation; Oligopeptides; Proline; Protease Inhibitors; Protein Structure, Tertiary; Quinolines; Recombinant Proteins; Sulfonamides; Thiazoles; Viral Nonstructural Proteins | 2014 |
A new stochastic model for subgenomic hepatitis C virus replication considers drug resistant mutants.
Topics: Antiviral Agents; Carbamates; Drug Resistance, Viral; Hepacivirus; Macrocyclic Compounds; Models, Statistical; Oligopeptides; Polymorphism, Single Nucleotide; Proline; Protease Inhibitors; Quinolines; Replicon; RNA, Viral; Stochastic Processes; Thiazoles; Viral Nonstructural Proteins; Virus Replication | 2014 |
HCV therapy with daclatasvir, PEG-IFN, and RBV after boceprevir-based therapy failure post-liver transplantation in hyper-IgM syndrome.
Topics: Adult; Antiviral Agents; Carbamates; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Hyper-IgM Immunodeficiency Syndrome; Imidazoles; Immunoglobulin M; Interferon-alpha; Liver Transplantation; Male; Polyethylene Glycols; Proline; Pyrrolidines; Recombinant Proteins; Ribavirin; Valine | 2014 |
Therapy of hepatitis C--back to the future.
Topics: Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Sulfonamides; Valine | 2014 |
Hepatitis C virus cell-cell transmission and resistance to direct-acting antiviral agents.
Topics: Antibodies, Neutralizing; Antiviral Agents; Carbamates; Cell Communication; Cells, Cultured; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Imidazoles; Oligopeptides; Proline; Pyrrolidines; Valine; Viral Load; Virus Internalization | 2014 |
A high-throughput, multiplexed assay for superfamily-wide profiling of enzyme activity.
Topics: Animals; Boronic Acids; Carbamates; Carboxylic Ester Hydrolases; Dipeptidyl-Peptidase IV Inhibitors; Drug Discovery; Enzyme Inhibitors; Female; Glucose Tolerance Test; Glutamates; High-Throughput Screening Assays; Humans; Lipopolysaccharides; Macaca fascicularis; Male; Mice, Inbred C57BL; Nitriles; Oligopeptides; Piperazines; Proline; Serine Proteases; Serine Proteinase Inhibitors | 2014 |
Low relapse rate leads to high concordance of sustained virologic response (SVR) at 12 weeks with SVR at 24 weeks after treatment with ABT-450/ritonavir, ombitasvir, and dasabuvir plus ribavirin in subjects with chronic hepatitis C virus genotype 1 infect
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Recurrence; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Uracil; Valine; Viral Load | 2015 |
In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A.
Topics: Anilides; Antiviral Agents; Carbamates; Cell Line; Drug Resistance, Viral; Hepacivirus; Hepatitis C; Humans; Proline; Valine | 2015 |
Dasabuvir : a new direct antiviral agent for the treatment of hepatitis C.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Hepatitis C; Humans; Interferon-alpha; Lactams, Macrocyclic; Macrocyclic Compounds; Polyethylene Glycols; Proline; Ribavirin; RNA-Dependent RNA Polymerase; Sulfonamides; Uracil; Valine | 2015 |
A 4-drug combination (Viekira Pak) for hepatitis C.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Drug Interactions; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Thousands of patients in England to get new hepatitis C drugs.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; England; Fluorenes; Hepatitis C, Chronic; Heterocyclic Compounds, 3-Ring; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Simeprevir; Sofosbuvir; Sulfonamides; Uridine Monophosphate; Valine | 2015 |
Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Antiviral Therapy in Patients with Hepatitis C Virus-Induced Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Protease Inhibitors; Pyrrolidines; Ribavirin; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2015 |
[High chance for cure].
Topics: 2-Naphthylamine; Anilides; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Germany; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
T-cell homeostasis in chronic HCV-infected patients treated with interferon and ribavirin or an interferon-free regimen.
Topics: Adult; Aged; Amides; Antiviral Agents; Apoptosis; Benzofurans; Carbamates; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferon-alpha; Interleukin-7 Receptor alpha Subunit; Lipopolysaccharides; Lymphocyte Count; Lymphopenia; Male; Middle Aged; Oligopeptides; Polyethylene Glycols; Proline; Prospective Studies; Quinoxalines; Recombinant Proteins; Ribavirin; Sulfonamides | 2015 |
Suspected pharmacokinetic interaction between raltegravir and the 3D regimen of ombitasvir, dasabuvir and paritaprevir/ritonavir in an HIV-HCV liver transplant recipient.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Raltegravir Potassium; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Paritaprevir/ritonavir, ombitasvir, and dasabuvir for treatment of recurrent hepatitis C virus infection in the human immunodeficiency virus coinfected liver transplant recipient.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Genotype; Graft Survival; Hepacivirus; Hepatitis C; HIV Infections; Humans; Immunosuppressive Agents; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Recurrence; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Uracil; Valine | 2016 |
Drug Interactions Between Hepatoprotective Agents Ursodeoxycholic Acid or Glycyrrhizin and Ombitasvir/Paritaprevir/Ritonavir in Healthy Japanese Subjects.
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Glycyrrhizic Acid; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ritonavir; Sulfonamides; Ursodeoxycholic Acid; Valine; Young Adult | 2015 |
Cost-effectiveness of Ombitasvir/Paritaprevir/Ritonavir, Dasabuvir+Ribavirin for US Post-Liver Transplant Recurrent Genotype 1 HCV.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Costs; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Economic; Phenotype; Proline; Recurrence; Ribavirin; Risk Factors; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; United States; Uracil; Valine; Viral Load; Virus Activation | 2016 |
Paritaprevir/ritonavir/ombitasvir and dasabuvir for the treatment of chronic hepatitis C virus infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Coinfection; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2015 |
Severe Hyperbilirubinemia in an HIV-HCV-Coinfected Patient Starting the 3D Regimen That Resolved After TDM-Guided Atazanavir Dose Reduction.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Atazanavir Sulfate; Carbamates; Coinfection; Cyclopropanes; Dose-Response Relationship, Drug; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C; HIV Infections; HIV Protease Inhibitors; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Ombitasvir, paritaprevir, ritonavir, dasabuvir and ribavirin in cirrhosis after complete destruction of hepatocellular carcinoma.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Function Tests; Liver Neoplasms; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2016 |
Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir Plus Dasabuvir With or Without Ribavirin in HCV-Infected Patients Taking Concomitant Acid-Reducing Agents.
Topics: 2-Naphthylamine; Anilides; Antacids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Hydrogen-Ion Concentration; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Proton Pump Inhibitors; Randomized Controlled Trials as Topic; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2016 |
Cost-effectiveness of currently recommended direct-acting antiviral treatments in patients infected with genotypes 1 or 4 hepatitis C virus in the US.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Fibrosis; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Models, Econometric; Proline; Quality-Adjusted Life Years; Ribavirin; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2016 |
Ombitasvir/paritaprevir/ritonavir plus dasabuvir combination in the treatment of chronic HCV infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Darunavir-based Antiretroviral Therapy may Affect the Efficacy of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir in HCV/HIV-1 Coinfected Patients.
Topics: 2-Naphthylamine; Anilides; Carbamates; Coinfection; Cyclopropanes; Darunavir; Hepatitis C; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Economic evaluation of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic genotype 1 hepatitis c virus infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Markov Chains; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Metabolism and Disposition of Pan-Genotypic Inhibitor of Hepatitis C Virus NS5A Ombitasvir in Humans.
Topics: Administration, Oral; Anilides; Antiviral Agents; Biotransformation; Carbamates; Chromatography, High Pressure Liquid; Cytochrome P-450 CYP2C8; Drug Administration Schedule; Feces; Healthy Volunteers; Hepacivirus; Humans; Hydrolysis; Male; Oxidation-Reduction; Proline; Tandem Mass Spectrometry; Tissue Distribution; Valine; Viral Nonstructural Proteins | 2016 |
Effectiveness of Sofosbuvir, Ledipasvir/Sofosbuvir, or Paritaprevir/Ritonavir/Ombitasvir and Dasabuvir Regimens for Treatment of Patients With Hepatitis C in the Veterans Affairs National Health Care System.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Department of Veterans Affairs; Uracil; Uridine Monophosphate; Valine | 2016 |
Comparative effectiveness of ledipasvir/sofosbuvir ± ribavirin vs. ombitasvir/paritaprevir/ritonavir + dasabuvir ± ribavirin in 6961 genotype 1 patients treated in routine medical practice.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Black or African American; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2016 |
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Combinations; Female; Fluorenes; Health Services Accessibility; Hepacivirus; Hepatitis C; HIV Protease Inhibitors; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Markov Chains; Medicaid; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sofosbuvir; Sulfonamides; United States; Uracil; Uridine Monophosphate; Valine | 2016 |
Cost-Effectiveness of Genotype 1 Chronic Hepatitis C Virus Treatments in Patients Coinfected with Human Immunodeficiency Virus in the United States.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cost-Benefit Analysis; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Humans; Interferon-alpha; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Markov Chains; Middle Aged; Polyethylene Glycols; Proline; Quality-Adjusted Life Years; Recombinant Proteins; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; United States; Uracil; Valine | 2016 |
Cost-effectiveness of direct-acting antiviral regimen ombitasvir/paritaprevir/ritonavir in treatment-naïve and treatment-experienced patients infected with chronic hepatitis C virus genotype 1b in Japan.
Topics: Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Japan; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Economic; Proline; Ritonavir; Sulfonamides; Valine | 2016 |
Severe Elevation of Liver Enzymes Does Not Necessarily Require Treatment Interruption in Patients Treated With a Combination of Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for HCV Infection.
Topics: 2-Naphthylamine; Alanine Transaminase; Anilides; Antiviral Agents; Aspartate Aminotransferases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Withholding Treatment | 2016 |
Effectiveness and Safety of Ombitasvir-Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin for HCV Genotype 1 Infection for 12 Weeks Under Routine Clinical Practice.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2016 |
Breast Hypertrophy Induced by Ombitasvir/Paritaprevir/Ritonavir and Ribavirina.
Topics: Anilides; Antiviral Agents; Breast Diseases; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Hypertrophy; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine | 2016 |
Falling up stairs.
Topics: 2-Naphthylamine; Accidental Falls; Anilides; Antiviral Agents; Bronchodilator Agents; Carbamates; Cushing Syndrome; Cyclopropanes; Drug Therapy, Combination; Fluticasone; Hepatitis C; Humans; Hydrocortisone; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Salmeterol Xinafoate; Sulfonamides; Uracil; Valine | 2016 |
Ombitasvir-Paritaprevir-Ritonavir-Dasabuvir (Viekira Pak)-Induced Lactic Acidosis.
Topics: 2-Naphthylamine; Acidosis, Lactic; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Fluid Therapy; Hemofiltration; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Respiration, Artificial; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
Population pharmacokinetics of paritaprevir, ombitasvir, dasabuvir, ritonavir and ribavirin in hepatitis C virus genotype 1 infection: analysis of six phase III trials.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Combinations; Female; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Models, Biological; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
HCV Resistance Profile Evolution in a GT1b, DAA-Naive Patient Before, On, and After Failing Triple DAA Therapy.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; Drug Combinations; Drug Resistance, Viral; Hepacivirus; Hepatitis C, Chronic; High-Throughput Nucleotide Sequencing; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uracil; Valine; Viral Nonstructural Proteins | 2017 |
Predictable threats to public health through delaying universal access to innovative medicines for hepatitis C: a pharmaceutical standpoint.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Industry; Drug Therapy, Combination; Fees, Pharmaceutical; Fluorenes; Health Services Accessibility; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Public Health; Pyrrolidines; Quality Assurance, Health Care; Quality Control; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2016 |
First Case in Kazakhstan of Successful Therapy With 2 Consecutive Direct-Acting Antiviral Regimens in a Patient with Hepatitis C Virus-Induced Decompensated Liver Cirrhosis on a Liver Transplant Wait List.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Kazakhstan; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Medication Adherence; Proline; Recurrence; Retreatment; Ritonavir; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Waiting Lists | 2016 |
Paritaprevir/ritonavir/ombitasvir+dasabuvir plus ribavirin therapy and inhibition of the anticoagulant effect of warfarin: a case report.
Topics: 2-Naphthylamine; Anilides; Anticoagulants; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Warfarin | 2017 |
An Integrative Drug Repurposing Pipeline: Switching Viral Drugs to Breast Cancer.
Topics: Anilides; Antineoplastic Agents; Antiviral Agents; Breast Neoplasms; Carbamates; Computational Biology; Drug Repositioning; Drug Resistance, Neoplasm; Drug Screening Assays, Antitumor; Female; Humans; Hydrophobic and Hydrophilic Interactions; Models, Molecular; Molecular Docking Simulation; Mutation; Paclitaxel; Polypharmacology; Proline; Tubulin; Valine | 2017 |
Real-life efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir in chronic hepatitis C patients in Hong Kong.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; Hong Kong; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Time Factors; Treatment Outcome; Uracil; Valine | 2017 |
Four weeks of paritaprevir/ritonavir/ombitasvir plus dasabuvir encountering dengue fever resulted in sustained virological response in an HCV patient: A case report.
Topics: 2-Naphthylamine; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Dengue; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Viral Load | 2016 |
Hepatitis C Treatment With Direct-Acting Antivirals in Kidney Transplant: Preliminary Results From a Multicenter Study.
Topics: Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Fluorenes; Hepacivirus; Hepatitis C; Humans; Imidazoles; Immunosuppression Therapy; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Postoperative Complications; Proline; Prospective Studies; Pyrrolidines; Retrospective Studies; Ribavirin; Simeprevir; Sofosbuvir; Spain; Sulfonamides; Treatment Outcome; Valine | 2016 |
Time to viral suppression is not related to achievement of SVR12 in HCV GT1-infected patients treated with ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin.
Topics: Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Male; Middle Aged; Proline; RNA, Viral; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Young Adult | 2017 |
A Case of Acute Liver Failure during Ritonavir-Boosted Paritaprevir, Ombitasvir and Dasabuvir Therapy in a Patient with HCV Genotype 1b Cirrhosis.
Topics: 2-Naphthylamine; Aged, 80 and over; Anilides; Antiviral Agents; Ascites; Carbamates; Chemical and Drug Induced Liver Injury; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Liver Cirrhosis; Liver Failure, Acute; Liver Function Tests; Macrocyclic Compounds; Male; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine | 2016 |
Combination Therapy with Ombitasvir/Paritaprevir/Ritonavir for Dialysis Patients Infected with Hepatitis C Virus: A Prospective Multi-Institutional Study.
Topics: Aged; Anilides; Carbamates; Cyclopropanes; Demography; Disease Progression; Drug Resistance, Viral; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Ritonavir; Sulfonamides; Valine | 2017 |
Successful retreatment of a patient with chronic hepatitis C genotype 2k/1b virus with ombitasvir/paritaprevir/ritonavir plus dasabuvir.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Prevalence; Proline; Retreatment; Ritonavir; Sulfonamides; Uracil; Valine; Viral Load | 2017 |
Progress in eradication of HCV in HIV positive patients with significant liver fibrosis in Vienna.
Topics: 2-Naphthylamine; Adult; AIDS-Related Opportunistic Infections; Anilides; Anti-HIV Agents; Antiviral Agents; Austria; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; HIV Seropositivity; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Uridine Monophosphate; Valine | 2017 |
Universal Sustained Viral Response to the Combination of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir with/without Ribavirin in Patients on Hemodialysis Infected with Hepatitis C Virus Genotypes 1 and 4.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Ribavirin; Ritonavir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2017 |
Effectiveness, safety and clinical outcomes of direct-acting antiviral therapy in HCV genotype 1 infection: Results from a Spanish real-world cohort.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Carcinoma, Hepatocellular; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Neoplasm Recurrence, Local; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult | 2017 |
Effectiveness of All-Oral Antiviral Regimens in 996 Human Immunodeficiency Virus/Hepatitis C Virus Genotype 1-Coinfected Patients Treated in Routine Practice.
Topics: Administration, Oral; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Practice Patterns, Physicians'; Proline; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uridine Monophosphate; Valine; Veterans | 2017 |
Effectiveness of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir in Hemodialysis Patients With Hepatitis C Virus Infection and Advanced Liver Fibrosis: Case Reports.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Ritonavir; Severity of Illness Index; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Real-world experience with the all-oral, interferon-free regimen of ombitasvir/paritaprevir/ritonavir and dasabuvir for the treatment of chronic hepatitis C virus infection in the German Hepatitis C Registry.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Germany; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Severity of Illness Index; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2017 |
Ultra-performance liquid chromatography tandem mass spectrometry for determination of Direct Acting Antiviral drugs in human liver fine needle aspirates.
Topics: 2-Naphthylamine; Anilides; Animals; Antiviral Agents; Carbamates; Chromatography, High Pressure Liquid; Cyclopropanes; Humans; Lactams, Macrocyclic; Limit of Detection; Liver; Macrocyclic Compounds; Needles; Proline; Reproducibility of Results; Sulfonamides; Tandem Mass Spectrometry; Uracil; Valine | 2017 |
Exposure-Safety Response Relationship for Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Ribavirin in Patients with Chronic Hepatitis C Virus Genotype 1 Infection: Analysis of Data from Five Phase II and Six Phase III Studies.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine; Young Adult | 2017 |
Real-World Safety and Efficacy of Ombitasvir/Paritaprevir/Ritonavir/+Dasabuvir±Ribavirin (OBV/PTV/r/+DSV±RBV) Therapy in Recurrent Hepatitis C Virus (HCV) Genotype 1 Infection Post-Liver Transplant: AMBER-CEE Study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Postoperative Complications; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
Real-world efficacy and safety of ritonavir-boosted paritaprevir, ombitasvir, dasabuvir ± ribavirin for hepatitis C genotype 1 - final results of the REV1TAL study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Bilirubin; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Mechanisms and Predictions of Drug-Drug Interactions of the Hepatitis C Virus Three Direct-Acting Antiviral Regimen: Paritaprevir/Ritonavir, Ombitasvir, and Dasabuvir.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbamates; Cell Line; Cyclopropanes; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Drug Interactions; Female; HEK293 Cells; Hepacivirus; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Membrane Transport Proteins; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
Ombitasvir, paritaprevir, and ritonavir, with or without dasabuvir, plus ribavirin for patients with hepatitis C virus genotype 1 or 4 infection with cirrhosis (ABACUS): a prospective observational study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Compassionate Use Trials; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Longitudinal Studies; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
The Influence of Hepatitis C Virus Therapy on the DNA Base Excision Repair System of Peripheral Blood Mononuclear Cells.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cell Nucleus; Cyclopropanes; Deoxyuridine; DNA; DNA Breaks, Double-Stranded; DNA Glycosylases; DNA Repair; DNA-(Apurinic or Apyrimidinic Site) Lyase; Drug Therapy, Combination; Endonucleases; Gene Expression; Hepacivirus; Hepatitis C, Chronic; Host-Pathogen Interactions; Humans; Lactams, Macrocyclic; Leukocytes, Mononuclear; Macrocyclic Compounds; Mitochondria; Molecular Mimicry; Primary Cell Culture; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
Effectiveness of a fixed combination formula of ombitasvir/paritaprevir/ritonavir for hepatitis C virus infection in patients on maintenance haemodialysis.
Topics: Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Disease Progression; Drug Combinations; Drug Compounding; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Japan; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Renal Insufficiency, Chronic; Ritonavir; RNA, Viral; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load | 2017 |
Emergence of drug resistance-associated variants and changes in serum lipid profiles in sofosbuvir plus ledipasvir-treated chronic hepatitis C patients.
Topics: Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Fluorenes; Genetic Variation; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Lipids; Macrocyclic Compounds; Male; Middle Aged; Mutation; Proline; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Uridine Monophosphate; Valine; Young Adult | 2017 |
Paritaprevir/ritonavir/ombitasvir plus dasabuvir with ribavirin for treatment of recurrent chronic hepatitis C genotype 1 infection after liver transplantation: Real-world experience.
Topics: 2-Naphthylamine; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Postoperative Period; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Effectiveness of dasabuvir/ombitasvir/paritaprevir/ritonavir for hepatitis C virus in clinical practice: A population-based observational study.
Topics: 2-Naphthylamine; Aged; Anilides; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Uracil; Valine; Viral Load | 2017 |
Managing Drug-Drug Interaction Between Ombitasvir, Paritaprevir/Ritonavir, Dasabuvir, and Mycophenolate Mofetil.
Topics: 2-Naphthylamine; Aged; Anilides; Antibiotics, Antineoplastic; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Disease Management; Drug Interactions; Drug Monitoring; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Mycophenolic Acid; Proline; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
Hepatitis B reactivation in a patient with chronic hepatitis C treated with direct-acting antivirals.
Topics: Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Guanine; Hepatitis B virus; Hepatitis B, Chronic; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Protease Inhibitors; Ribavirin; Ritonavir; Sulfonamides; Valine; Viral Load; Viral Nonstructural Proteins; Viremia; Virus Activation | 2018 |
Real-world effectiveness and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with or without ribavirin for patients with chronic hepatitis C virus genotype 1b infection in Taiwan.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Safety; Sulfonamides; Taiwan; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
Effect of Paritaprevir/Ritonavir/Ombitasvir/Dasabuvir and Ledipasvir/Sofosbuvir Regimens on Survival Compared With Untreated Hepatitis C Virus-Infected Persons: Results From ERCHIVES.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepatitis C, Chronic; Humans; Kaplan-Meier Estimate; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Propensity Score; Proportional Hazards Models; Ritonavir; Sofosbuvir; Sulfonamides; Survival Rate; Sustained Virologic Response; Uracil; Valine | 2017 |
Successful twice interrupted therapy of HCV infection in patients with cirrhosis with hepatocellular carcinoma before and after liver transplantation.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2017 |
Real-Life Use of 3 Direct-Acting Antiviral Regimen in a Large Cohort of Patients with Genotype-1b HCV Compensated Cirrhosis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Elasticity Imaging Techniques; Female; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Romania; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine | 2017 |
Successful treatment of chronic hepatitis C virus infection in a patient receiving daily peritoneal dialysis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Combinations; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Peritoneal Dialysis; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2017 |
Mavyret and Vosevi--two new combinations for chronic HCV infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome | 2017 |
Anti-HCV treatment with ombitasvir/paritaprevir/ritonavir ± dasabuvir is associated with increased bile acid levels and pruritus.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Bile Acids and Salts; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Pruritus; Ritonavir; Sulfonamides; Uracil; Valine | 2017 |
Sustained virological response to ombitasvir/paritaprevir/ritonavir and dasabuvir treatment for hepatitis C: Real-world data from a large healthcare provider.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Potential drug-drug interactions of OMBITASVIR, PARITAPREVIR/ritonavir ± DASABUVIR ± ribavirin in clinical practice.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Drug-Related Side Effects and Adverse Reactions; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
The outcomes of glucose abnormalities in chronic hepatitis C patients receiving interferon-free direct antiviral agents.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Glucose; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Insulin Resistance; Insulin-Secreting Cells; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2017 |
Benefit-risk assessment for sofosbuvir/velpatasvir/voxilaprevir based on patient population and hepatitis C virus genotype: U. S. Food and Drug Administration's evaluation.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Risk Assessment; Sofosbuvir; Sulfonamides; Sustained Virologic Response; United States; United States Food and Drug Administration; Viral Nonstructural Proteins | 2018 |
New Oral HCV Drug.
Topics: Administration, Oral; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Contraindications, Drug; Cyclopropanes; Drug Approval; Drug Combinations; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2017 |
Plasma trough concentrations of antiretrovirals in HIV-infected persons treated with direct-acting antiviral agents for hepatitis C in the real world.
Topics: 2-Naphthylamine; Anilides; Anti-Retroviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Hepatitis C, Chronic; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Proline-Based Carbamates as Cholinesterase Inhibitors.
Topics: Acetylcholinesterase; Binding Sites; Butyrylcholinesterase; Carbamates; Catalytic Domain; Cholinesterase Inhibitors; Molecular Conformation; Molecular Docking Simulation; Proline; Protein Binding; Structure-Activity Relationship | 2017 |
Patient-Reported Outcomes Following Treatment of Chronic Hepatitis C Virus Infection With Sofosbuvir and Velpatasvir, With or Without Voxilaprevir.
Topics: Adult; Aged; Aged, 80 and over; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Placebos; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Surveys and Questionnaires; Sustained Virologic Response | 2018 |
Sofosbuvir and velpatasvir with or without voxilaprevir in direct-acting antiviral-naïve chronic hepatitis C: patient-reported outcomes from POLARIS 2 and 3.
Topics: Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Clinical Trials, Phase III as Topic; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Multicenter Studies as Topic; Patient Reported Outcome Measures; Proline; Quinoxalines; Randomized Controlled Trials as Topic; Self Report; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2018 |
Biochemical Basis of Vosevi, a New Treatment for Hepatitis C
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Hepacivirus; Hepatitis; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Serine Proteases; Sofosbuvir; Sulfonamides; Viral Nonstructural Proteins | 2018 |
Remarkable plasma HIV RNA decrease by ombitasvir/paritaprevir/ritonavir in an HIV-HCV coinfection case.
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Plasma; Proline; Ritonavir; RNA, Viral; Sulfonamides; Valine; Viral Load | 2018 |
New hepatitis C virus genotype 1 subtype naturally harbouring resistance-associated mutations to NS5A inhibitors.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Drug Resistance, Viral; Equatorial Guinea; Female; Fluorenes; Gene Expression; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Microbial Sensitivity Tests; Middle Aged; Mutation; Phylogeny; Proline; Pyrrolidines; Sequence Analysis, DNA; Sulfonamides; Uracil; Valine; Viral Nonstructural Proteins | 2018 |
Differences in the Serum 4β-hydroxycholesterol Levels of Patients with Chronic Hepatitis C Virus (HCV) Infection: A Possible Impact on the Efficacy and Safety of Interferon (IFN)-free Treatment.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Case-Control Studies; Cyclopropanes; Cytochrome P-450 CYP3A; Drug Therapy, Combination; Female; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Hydroxycholesterols; Imidazoles; Interferons; Isoquinolines; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sex Factors; Sulfonamides; Treatment Failure; Valine | 2018 |
High Efficacy of ombitasvir/paritaprevir/ritonavir plus dasabuvir in hepatitis C genotypes 4 and 1-infected patients with severe chronic kidney disease.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; Saudi Arabia; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2018 |
Role of ribavirin in the treatment of hepatitis C virus-associated mixed cryoglobulinemia with interferon-free regimens.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
New Drugs 2018, part 1.
Topics: Aminoisobutyric Acids; Antibodies, Monoclonal; Antibodies, Neutralizing; Antipyrine; Benzamides; Benzimidazoles; Broadly Neutralizing Antibodies; Carbamates; Cyclopropanes; Drug Approval; Drug Combinations; Edaravone; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Naltrexone; Natriuretic Peptides; Proline; Pyridines; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; United States; United States Food and Drug Administration | 2018 |
Twelve weeks of ombitasvir/paritaprevir/r and dasabuvir without ribavirin is effective and safe in the treatment of patients with HCV genotype 1b infection and compensated cirrhosis: results from a real-world cohort study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection-Author's reply.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Editorial: direct-acting antivirals significantly improve quality of life in patients with hepatitis C virus infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Patient Reported Outcome Measures; Proline; Quality of Life; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Efficacy and safety of paritaprevir/ritonavir, ombitasvir, and dasabuvir with ribavirin for the treatment of HCV genotype 1b compensated cirrhosis in patients aged 70 years or older.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2017 |
Design, synthesis and identification of silicon-containing HCV NS5A inhibitors with pan-genotype activity.
Topics: Anilides; Animals; Antiviral Agents; Carbamates; Dogs; Drug Design; Enzyme Inhibitors; Genotype; Hepacivirus; Hepatitis C; Humans; Proline; Silicon; Valine; Viral Nonstructural Proteins | 2018 |
12 weeks ombitasvir/paritaprevir-ritonavir + ribavirin achieve high SVR rates in HCV-4 patients with advanced fibrosis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Italy; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
HCV genotype-3h, a difficult-to-diagnose sub-genotype in the DAA era.
Topics: 2-Naphthylamine; Aged; Amino Acid Substitution; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Resistance, Viral; Drug Therapy, Combination; Female; Follow-Up Studies; Gene Expression; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Isoenzymes; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Polymorphism, Genetic; Proline; Recurrence; Ribavirin; Sulfonamides; Treatment Failure; Uracil; Valine; Viral Load; Viral Nonstructural Proteins | 2018 |
Real-life 3D therapy failure: Analysis of NS5A 93H RAS plus 108 K polymorphism in complex with ombitasvir by molecular modeling.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Hepatitis C, Chronic; Humans; Male; Models, Molecular; Molecular Dynamics Simulation; Mutation, Missense; Polymorphism, Genetic; Proline; Recurrence; Treatment Failure; Valine; Viral Nonstructural Proteins | 2018 |
A Patient with HCV Infection and a Sustained Virological Response to Direct-acting Antiviral Treatment Who Developed Inclusion Body Myositis.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Myositis, Inclusion Body; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2018 |
Sofosbuvir + velpatasvir + voxilaprevir for the treatment of hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2018 |
Ombitasvir-Paritaprevir-Ritonavir Therapy in a Kidney Transplant Recipient With Chronic Hepatitis C Virus Genotype 1 Infection: A Case Report on the Importance of Considering Drug-Drug Interactions and Monitoring Cyclosporine Levels.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Valine | 2018 |
Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir Regimen in the Treatment of Genotype 1 Chronic Hepatitis C Infection in Patients with Severe Renal Impairment and End-Stage Renal Disease: a Real-Life Cohort.
Topics: 2-Naphthylamine; Anilides; Antihypertensive Agents; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Insufficiency; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Successful Ombitasvir/Paritaprevir/Ritonavir Plus Ribavirin Retreatment for a Chronic Hepatitis C Genotype 2a Patient Who Relapsed after Sofosbuvir Plus Ribavirin Treatment.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Valine | 2018 |
The Real-world Efficacy and Safety of Ombitasvir/Paritaprevir/Ritonavir for Hepatitis C Genotype 1.
Topics: Adult; Aged; Alanine Transaminase; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Treatment Outcome; Valine | 2018 |
Safety and efficacy of ombitasvir/paritaprevir/ritonavir/dasabuvir plus ribavirin in patients over 65 years with HCV genotype 1 cirrhosis.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Biomarkers; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Retreatment of hepatitis C virus: can it get any better?
Topics: Aminoisobutyric Acids; Carbamates; Cyclopropanes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2018 |
Ombitasvir/paritaprevir/ritonavir plus dasabuvir regimen may be used safely in combination with sirolimus for the treatment of chronic hepatitis C.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; End Stage Liver Disease; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Proline; Ritonavir; Sirolimus; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Durability of virologic response, risk of de novo hepatocellular carcinoma, liver function and stiffness 2 years after treatment with ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin in the AMBER, real-world experience study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Poland; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine; Viral Load | 2018 |
100% sustained virological response and fibrosis improvement in real-life use of direct acting antivirals in genotype-1b recurrent hepatitis C following liver transplantation.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Uridine Monophosphate; Valine | 2018 |
Concomitant use of sorafenib with ombitasvir/paritaprevir/ritonavir and dasabuvir: Effectiveness and safety in clinical practice.
Topics: 2-Naphthylamine; Aged; Anilides; Antineoplastic Agents; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Neoplasms; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ritonavir; Sorafenib; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Three renal failure cases successfully treated with ombitasvir/paritaprevir/ritonavir for genotype 1b hepatitis C virus reinfection after liver transplantation.
Topics: Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Monitoring; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Valine; Virus Activation | 2019 |
Editorial: is sofosbuvir-based therapy suitable for patients with advanced chronic kidney disease?
Topics: 2-Naphthylamine; Anilides; Benzimidazoles; Carbamates; Cyclopropanes; Fluorenes; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Proline; Renal Insufficiency, Chronic; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2018 |
Hepatic decompensation during paritaprevir/ritonavir/ombitasvir/dasabuvir treatment for genotype 1b chronic hepatitis C patients with advanced fibrosis and compensated cirrhosis.
Topics: 2-Naphthylamine; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cohort Studies; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Hyperbilirubinemia; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Risk Factors; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
Eight weeks of Paritaprevir/r/Ombitasvir + Dasabuvir in HCV genotype 1b with mild-moderate fibrosis: Results from a real-world cohort.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Spain; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Viral Load; Young Adult | 2019 |
Efficacy of ombitasvir/paritaprevir/ritonavir/ribavirin in management of HCV genotype 4 and end-stage kidney disease.
Topics: Adult; Aged, 80 and over; Algorithms; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Valine | 2019 |
Elimination of hepatitis C virus infection from a hemodialysis unit and impact of treatment on the control of anemia.
Topics: 2-Naphthylamine; Anemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Darbepoetin alfa; Female; Hematinics; Hematocrit; Hemoglobin A; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Renal Dialysis; Renal Insufficiency, Chronic; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
The choice of antiviral therapy for hepatitis C recurrence after liver transplantation in the real world.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Transplantation; Macrocyclic Compounds; Proline; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2018 |
Oral direct-acting antiviral therapy for hepatitis C virus infection in X-linked agammaglobulinemia.
Topics: 2-Naphthylamine; Administration, Oral; Adult; Agammaglobulinemia; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genetic Diseases, X-Linked; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Immunoglobulin G; Immunoglobulins, Intravenous; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Pyrrolidines; Ritonavir; Sofosbuvir; Sulfonamides; Uracil; Valine | 2019 |
Paritaprevir, ritonavir, ombitasvir, and dasabuvir with and without ribavirin in people with HCV genotype 1 and recent injecting drug use or receiving opioid substitution therapy.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Administration Schedule; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Medication Adherence; Middle Aged; Opiate Substitution Treatment; Proline; Qualitative Research; Ribavirin; Ritonavir; RNA, Viral; Substance Abuse, Intravenous; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2018 |
The efficacy of paritaprevir/ritonavir/ombitasvir+dasabuvir and ledipasvir/sofosbuvir is comparable in patients who failed interferon-based treatment with first generation protease inhibitors - a multicenter cohort study.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cohort Studies; Cyclopropanes; Drug Resistance, Multiple, Viral; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Humans; Interferons; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Poland; Proline; Protease Inhibitors; Ritonavir; Sofosbuvir; Sulfonamides; Treatment Outcome; Uracil; Uridine Monophosphate; Valine; Young Adult | 2018 |
Ombitasvir/paritaprevir/ritonavir+dasabuvir and ribavirin associated drug-induced liver injury and syndrome of inappropriate secretion of anti-diuretic hormone: A case report.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Chemical and Drug Induced Liver Injury; Creatinine; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Function Tests; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sodium; Sulfonamides; Uracil; Valine | 2019 |
The Successful Retreatment with Glecaprevir and Pibrentasvir of Genotype 1 or 2 HCV-infected Hemodialysis Patients who Failed to Respond to NS5A and Protease Inhibitor Treatment.
Topics: Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Imidazoles; Isoquinolines; Lactams, Macrocyclic; Leucine; Middle Aged; Proline; Protease Inhibitors; Pyrrolidines; Quinoxalines; Renal Dialysis; Retreatment; Sulfonamides; Treatment Failure; Valine | 2019 |
Effectiveness of ombitasvir/paritaprevir/ritonavir, dasabuvir for HCV in HIV/HCV coinfected subjects: a comprehensive analysis.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Clinical Trials as Topic; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; HIV; HIV Infections; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Observational Studies as Topic; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
Real-life results of treatment with ombitasvir, paritaprevir, dasabuvir, and ritonavir combination in patients with chronic renal failure infected with HCV in Turkey.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Ritonavir; Sulfonamides; Sustained Virologic Response; Turkey; Uracil; Valine | 2019 |
Effectiveness of fixed-dose combination of paritaprevir, ritonavir, ombitasvir, and dasabuvir in patients with chronic hepatitis C virus infection and chronic kidney diseases: real-life experiences.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Insufficiency, Chronic; Retrospective Studies; Ritonavir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2019 |
Successful Treatment With Direct-Acting Antiviral Agents of Hepatitis C in Patients With End-Stage Renal Disease and Kidney Transplant Recipients.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Immunosuppressive Agents; Kidney Failure, Chronic; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Retrospective Studies; Ribavirin; Risk Factors; Ritonavir; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine | 2019 |
Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studi
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Interactions; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Internationality; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2019 |
Evaluation of brain volume alterations in HCV-infected patients after interferon-free therapy: A pilot study.
Topics: Adult; Aged; Anilides; Antiviral Agents; Attention; Brain; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Magnetic Resonance Imaging; Male; Memory, Short-Term; Middle Aged; Neuropsychological Tests; Organ Size; Pilot Projects; Proline; Ritonavir; Sulfonamides; Valine | 2019 |
Ritonavir-boosted paritaprevir, ombitasvir plus ribavirin could improve eGFR in patients with renal impairment and HCV: an Egyptian cohort.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt; Female; Genotype; Glomerular Filtration Rate; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Recovery of Function; Renal Dialysis; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Valine; Viral Load; Young Adult | 2019 |
Paritaprevir/ritonavir, ombitasvir plus dasabuvir for East Asian non-cirrhotic hepatitis C virus genotype 1b patients receiving hemodialysis.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Middle Aged; Proline; Renal Dialysis; Ritonavir; Sulfonamides; Valine; Young Adult | 2019 |
The change in liver stiffness, controlled attenuation parameter and fibrosis-4 index for chronic hepatitis C patients with direct-acting antivirals.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Transaminases; Treatment Outcome; Uracil; Valine | 2019 |
Contemporary HCV pangenotypic DAA treatment protocols are exclusionary to real world HIV-HCV co-infected patients.
Topics: Adult; Aged; Aminoisobutyric Acids; Anti-Retroviral Agents; Antiviral Agents; Benzimidazoles; Carbamates; Coinfection; Cyclopropanes; Drug Interactions; Female; Hepacivirus; Hepatitis C; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Outcome; Viral Load | 2019 |
Real-world safety and efficacy of paritaprevir/ritonavir/ombitasvir plus dasabuvir ± ribavirin in patients with hepatitis C virus genotype 1 and advanced hepatic fibrosis or compensated cirrhosis: a multicenter pooled analysis.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2019 |
Sofosbuvir/Velpatasvir/Voxilaprevir for Previous Treatment Failures With Glecaprevir/Pibrentasvir in Chronic Hepatitis C Infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Male; Proline; Pyrrolidines; Quinoxalines; RNA, Viral; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Failure; Treatment Outcome | 2019 |
Patient-reported symptoms during and after direct-acting antiviral therapies for chronic hepatitis C: The PROP UP study.
Topics: 2-Naphthylamine; Adult; Aged; Aged, 80 and over; Amides; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Fluorenes; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Patient Reported Outcome Measures; Proline; Prospective Studies; Quinoxalines; Ritonavir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2019 |
[EFFICACY AND SAFETY OF OMBITASVIR/PARITAPREVIR/RITONAVIR AND DASABUVIR IN PATIENTS WITH HCV 1B GENOTYPE INFECTION: REAL WORLD DATA].
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Ukraine; Uracil; Valine | 2019 |
Discovery of the pan-genotypic hepatitis C virus NS3/4A protease inhibitor voxilaprevir (GS-9857): A component of Vosevi
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Dose-Response Relationship, Drug; Drug Combinations; Drug Discovery; Hepacivirus; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Microbial Sensitivity Tests; Molecular Structure; Proline; Protease Inhibitors; Quinoxalines; Sofosbuvir; Structure-Activity Relationship; Sulfonamides; Viral Nonstructural Proteins | 2019 |
A Cost-Effectiveness Analysis of Shortened Direct-Acting Antiviral Treatment in Genotype 1 Noncirrhotic Treatment-Naive Patients With Chronic Hepatitis C Virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Decision Trees; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Markov Chains; Proline; Quinoxalines; Sofosbuvir; State Medicine; Sulfonamides; United Kingdom | 2019 |
Recurrence rate of hepatocellular carcinoma in patients with treated hepatocellular carcinoma and hepatitis C virus-associated cirrhosis after ombitasvir/paritaprevir/ritonavir+dasabuvir+ribavirin therapy.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Carcinoma, Hepatocellular; Chemoembolization, Therapeutic; Cyclopropanes; Hepatectomy; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Liver Neoplasms; Macrocyclic Compounds; Middle Aged; Neoplasm Recurrence, Local; Proline; Prospective Studies; Radiofrequency Ablation; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2019 |
High efficacy of resistance-guided retreatment of HCV patients failing NS5A inhibitors in the real world.
Topics: Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Female; Fluorenes; Genotype; Hepacivirus; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Retreatment; Ribavirin; Ritonavir; Sofosbuvir; Spain; Sulfonamides; Sustained Virologic Response; Valine; Viral Nonstructural Proteins | 2019 |
Treatment of hepatitis C infection among Egyptian hemodialysis patients: the dream becomes a reality.
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Combinations; Egypt; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Renal Dialysis; Ritonavir; Sulfonamides; Treatment Outcome; Valine | 2019 |
Paritaprevir, ritonavir, ombitasvir, and dasabuvir treatment in renal transplant patients with hepatitis C virus infection.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Female; Hepacivirus; Hepatitis C; Humans; Kidney Transplantation; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Postoperative Complications; Proline; Ritonavir; Sulfonamides; Sustained Virologic Response; Tacrolimus; Uracil; Valine | 2019 |
Effectiveness, safety/tolerability of OBV/PTV/r ± DSV in patients with HCV genotype 1 or 4 with/without HIV-1 co-infection, chronic kidney disease (CKD) stage IIIb-V and dialysis in Spanish clinical practice - Vie-KinD study.
Topics: 2-Naphthylamine; Aged; Anilides; Antiviral Agents; Carbamates; Coinfection; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Renal Dialysis; Renal Insufficiency, Chronic; Retrospective Studies; Ribavirin; Ritonavir; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2019 |
Hepatitis C therapy with direct antiviral agents in patients with advanced chronic kidney disease: real-world experience of the German Hepatitis C-Registry (Deutsches Hepatitis C-Register).
Topics: 2-Naphthylamine; Acute Disease; Adult; Aged; Anemia; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Disease Progression; Drug Therapy, Combination; Female; Fluorenes; Germany; Glomerular Filtration Rate; Hepatitis C, Chronic; Humans; Hypertension; Imidazoles; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Male; Middle Aged; Pleural Effusion; Proline; Pyrrolidines; Registries; Renal Insufficiency, Chronic; Ribavirin; Ritonavir; RNA, Viral; Severity of Illness Index; Simeprevir; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Uridine Monophosphate; Valine | 2019 |
Au(iii)-Proline derivatives exhibiting selective antiproliferative activity against HepG2/SB3 apoptosis-resistant cancer cells.
Topics: Antigens, Neoplasm; Antineoplastic Agents; Apoptosis; Carbamates; Carcinoma, Hepatocellular; Cell Line, Tumor; Coordination Complexes; Gold; Humans; Liver Neoplasms; Proline; Serpins | 2019 |
Development and Validation of a New LC-MS/MS Analytical Method for Direct-Acting Antivirals and Its Application in End-Stage Renal Disease Patients.
Topics: Adult; Anilides; Antiviral Agents; Carbamates; Chromatography, Liquid; Cyclopropanes; Drug Stability; Female; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Mass Spectrometry; Middle Aged; Plasma; Proline; Ritonavir; Sulfonamides; Valine | 2020 |
Real-world evidence of the effectiveness of ombitasvir-paritaprevir/r ± dasabuvir ± ribavirin in patients monoinfected with chronic hepatitis C or coinfected with human immunodeficiency virus-1 in Spain.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Hepatitis C, Chronic; HIV Infections; HIV-1; Humans; Lactams, Macrocyclic; Logistic Models; Macrocyclic Compounds; Male; Middle Aged; Multivariate Analysis; Proline; Ribavirin; Spain; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Uracil; Valine | 2019 |
Three Children Treated with Direct-acting Antivirals for Chronic Hepatitis C Virus Genotype 1b Infection.
Topics: Adolescent; Aminoisobutyric Acids; Anilides; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Pyrrolidines; Quinoxalines; Sulfonamides; Sustained Virologic Response; Treatment Outcome; Valine | 2020 |
Comparative effectiveness of 8 versus 12 weeks of Ombitasvir/Paritaprevir/ritonavir and Dasabuvir in treatment-naïve patients infected with HCV genotype 1b with non-advanced hepatic fibrosis.
Topics: 2-Naphthylamine; Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Follow-Up Studies; Genotype; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Male; Middle Aged; Prognosis; Proline; Retrospective Studies; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine; Young Adult | 2020 |
Molecular and Structural Mechanism of Pan-Genotypic HCV NS3/4A Protease Inhibition by Glecaprevir.
Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Catalytic Domain; Crystallography, X-Ray; Cyclopropanes; Hepacivirus; Lactams, Macrocyclic; Leucine; Mutation; Proline; Protein Binding; Quinoxalines; Serine Proteases; Serine Proteinase Inhibitors; Sulfonamides; Viral Nonstructural Proteins | 2020 |
Fast Cyclization of a Proline-Derived Self-Immolative Spacer Improves the Efficacy of Carbamate Prodrugs.
Topics: Antineoplastic Agents; Carbamates; Cell Line, Tumor; Cell Proliferation; Cyclization; Drug Screening Assays, Antitumor; Humans; Molecular Structure; Prodrugs; Proline | 2020 |
Safety and efficacy of direct-acting antivirals for chronic hepatitis C in patients with chronic kidney disease.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cryoglobulinemia; Cyclopropanes; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Lupus Erythematosus, Systemic; Male; Middle Aged; Proline; Prospective Studies; Renal Insufficiency, Chronic; Ritonavir; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2020 |
Cost-Effectiveness Analysis of Ombitasvir/Paritaprevir/Ritonavir and Dasabuvir With or Without Ribavirin Regimen for Patients Infected With Chronic Hepatitis C Virus Genotype 1 in Malaysia.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cost-Benefit Analysis; Cyclopropanes; Genotype; Hepatitis C; Humans; Lactams, Macrocyclic; Malaysia; Proline; Ribavirin; Ritonavir; Sulfonamides; Treatment Outcome; Uracil; Valine | 2020 |
Response to direct-acting antiviral agents in chronic hepatitis C patients with end-stage renal disease: a clinical experience.
Topics: 2-Naphthylamine; Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Ribavirin; Ritonavir; RNA, Viral; Statistics, Nonparametric; Sulfonamides; Sustained Virologic Response; Time Factors; Treatment Outcome; Uracil; Valine; Young Adult | 2019 |
English hepatitis C registry data show high response rates to directly acting anti-virals, even if treatment is not completed.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Anilides; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Combinations; England; Female; Fluorenes; Hepatitis C; Humans; Imidazoles; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Quinoxalines; Registries; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Uridine Monophosphate; Valine; Young Adult | 2020 |
Ombitasvir, Paritaprevir, Ritonavir, and Dasabuvir Mini-Tabs Plus Ribavirin for Children Aged 3-11 Years with Hepatitis C Genotype 1a.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Child; Child, Preschool; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Male; Proline; Ribavirin; Ritonavir; Sulfonamides; Tablets; Uracil; Valine | 2020 |
Sustained virological response following an 11-day course of direct acting antiviral therapy for hepatitis C infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cytochrome P-450 CYP3A Inhibitors; Drug Administration Schedule; Drug Therapy, Combination; Female; Hepatitis C, Chronic; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lactams, Macrocyclic; Middle Aged; Proline; Ritonavir; Simvastatin; Sulfonamides; Sustained Virologic Response; Uracil; Valine | 2020 |
Efficacy of sofosbuvir/velpatasvir/voxilaprevir in direct-acting antiviral experienced patients with hepatitis C virus.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; HIV Infections; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response | 2021 |
Sofosbuvir/velpatasvir/voxilaprevir plus ribavirin for chronic hepatitis C patients with direct acting antiviral failures: Implications for viral elimination in Taiwan.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Genotype; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Taiwan | 2020 |
Effectiveness of sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus infection and virologic failure to direct-acting antivirals.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Combinations; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2021 |
Efficacy and Safety of Sofosbuvir/Velpatasvir/Voxilaprevir for Hepatitis C Virus (HCV) NS5A-Inhibitor Experienced Patients With Difficult to Cure Characteristics.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2021 |
Sofosbuvir, velpatasvir, and voxilaprevir for patients with failure of previous direct-acting antiviral therapy for chronic hepatitis C: Results from the German Hepatitis C-Registry (DHC-R).
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Macrocyclic Compounds; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2020 |
Hepatitis C therapy with grazoprevir/elbasvir and glecaprevir/pibrentasvir in patients with advanced chronic kidney disease: data from the German Hepatitis C-Registry (DHC-R).
Topics: Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Imidazoles; Lactams, Macrocyclic; Leucine; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Registries; Renal Insufficiency, Chronic; Ribavirin; Sulfonamides; Sustained Virologic Response | 2022 |
Efficacy and safety of ombitasvir/paritaprevir/ritonavir/ribavirin in management of Egyptian chronic hepatitis C virus patients with chronic kidney disease: A real-life experience.
Topics: Adult; Aged; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Egypt; Female; Hepatitis C, Chronic; Humans; Kidney Failure, Chronic; Lactams, Macrocyclic; Macrocyclic Compounds; Male; Middle Aged; Proline; Prospective Studies; Ribavirin; Ritonavir; Sulfonamides; Sustained Virologic Response; Valine | 2020 |
Changing epidemiology of patients treated with direct acting antivirals for HCV and persistently high SVR12 in an endemic area for HCV infection in Italy: real-life 'LIver Network Activity' (LINA) cohort update results.
Topics: Adult; Age Distribution; Aged; Amides; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzofurans; Carbamates; Cyclopropanes; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Imidazoles; Italy; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Male; Middle Aged; Proline; Prospective Studies; Pyrrolidines; Quinoxalines; Retrospective Studies; Sulfonamides; Sustained Virologic Response | 2021 |
Salvage Therapy with Sofosbuvir/Velpatasvir/Voxilaprevir in DAA-experienced Patients: Results from a Prospective Canadian Registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Canada; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Prospective Studies; Quinoxalines; Registries; Salvage Therapy; Sofosbuvir; Sulfonamides | 2021 |
Resistance-associated substitutions after sofosbuvir/velpatasvir/voxilaprevir triple therapy failure.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Resistance, Viral; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Treatment Failure; Viral Nonstructural Proteins | 2021 |
Sofosbuvir/Velpatasvir Plus Ribavirin Combination Therapy for Patients with Hepatitis C Virus Genotype 1a, 2a, or 3b after Glecaprevir/Pibrentasvir Therapy Failed.
Topics: Aged; Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Cyclopropanes; Drug Therapy, Combination; Female; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Male; Middle Aged; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Outcome | 2021 |
Repurposing nonnucleoside antivirals against SARS-CoV2 NSP12 (RNA dependent RNA polymerase): In silico-molecular insight.
Topics: Amides; Antiviral Agents; Benzimidazoles; Carbamates; Catalytic Domain; Computer Simulation; Coronavirus RNA-Dependent RNA Polymerase; COVID-19; COVID-19 Drug Treatment; Cyclopropanes; Drug Evaluation, Preclinical; Drug Repositioning; Fluorenes; Humans; Lactams, Macrocyclic; Molecular Docking Simulation; Molecular Dynamics Simulation; Pandemics; Proline; Protein Conformation; Quinoxalines; SARS-CoV-2; Sulfonamides | 2021 |
Sofosbuvir/velpatasvir/voxilaprevir for hepatitis C virus retreatment in decompensated cirrhosis.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Retreatment; Sofosbuvir; Sulfonamides | 2021 |
[Glecaprevir/Pibrentasvir + Sofosbuvir + Ribavirin as a salvage regimen after Sofosbuvir + Velpatasvir + Voxilaprevir re-treatment failure].
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Pyrrolidines; Quinoxalines; Ribavirin; Sofosbuvir; Sulfonamides; Treatment Failure; Treatment Outcome | 2022 |
Drug-Drug Interactions With Cyclosporine in the Anti-Hepatitis C Viral PrOD Combination Regimen of Paritaprevir/Ritonavir-Ombitasvir and Dasabuvir in Organ Transplant Recipients With Severe Hepatic Fibrosis or Cirrhosis.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Cyclosporine; Drug Interactions; Drug Therapy, Combination; Hepacivirus; Hepatitis C; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Organ Transplantation; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2022 |
Sofosbuvir-velpatasvir-voxilaprevir in adolescents 12 to 17 years old with HCV infection.
Topics: Adolescent; Adult; Aminoisobutyric Acids; Antiviral Agents; Carbamates; Child; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Liver Cirrhosis; Proline; Quinoxalines; Sofosbuvir; Sulfonamides; Sustained Virologic Response; Treatment Outcome | 2022 |
hsa-miR-17-5p: A Possible Predictor of Ombitasvir/Paritaprevir/Ritonavir + Dasabuvir ± Ribavirin Therapy Efficacy in Hepatitis C Infection.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepatitis C; Humans; Lactams, Macrocyclic; Macrocyclic Compounds; MicroRNAs; Proline; Ribavirin; Ritonavir; RNA, Messenger; Sulfonamides; Toll-Like Receptor 2; Treatment Outcome; Uracil; Valine | 2022 |
Real-world effectiveness and safety of sofosbuvir/velpatasvir and glecaprevir/pibrentasvir for genotype 6 chronic hepatitis C.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Lipids; Proline; Pyrrolidines; Quinoxalines; Sofosbuvir; Sugars; Sulfonamides; Treatment Outcome | 2022 |
Efficacy and Safety of Ombitasvir/Paritaprevir/ Ritonavir + Dasabuvir ± Ribavirin Combinations in Patients with Genotype 1 Hepatitis C and Inherited Bleeding Disorders.
Topics: 2-Naphthylamine; Adult; Anilides; Antiviral Agents; Carbamates; Child; Cyclopropanes; Drug Therapy, Combination; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Retrospective Studies; Ribavirin; Ritonavir; Sulfonamides; Uracil; Valine | 2022 |
Treatment outcomes of sofosbuvir/velpatasvir/voxilaprevir among NS5A inhibitor-experienced patients with hepatitis C: Real-world data from a multicenter Asian registry.
Topics: Aminoisobutyric Acids; Antiviral Agents; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Registries; Sofosbuvir; Sulfonamides; Treatment Outcome | 2022 |
A Real-World Study to Compare the Safety and Efficacy of Paritaprevir/Ombitasvir/Ritonavir and Dasabuvir, with or without Ribavirin, in 587 Patients with Chronic Hepatitis C at the Fundeni Clinical Institute, Bucharest, Romania.
Topics: 2-Naphthylamine; Anilides; Antiviral Agents; Carbamates; Cyclopropanes; Drug Therapy, Combination; Hepacivirus; Hepatitis C, Chronic; Humans; Lactams, Macrocyclic; Liver Cirrhosis; Macrocyclic Compounds; Proline; Prospective Studies; Ribavirin; Ritonavir; Romania; Sulfonamides; Uracil; Valine | 2022 |
Non-responders to sofosbuvir/velpatasvir/voxilaprevir in the treatment of chronic hepatitis C infection.
Topics: Aminoisobutyric Acids; Antiviral Agents; Benzimidazoles; Benzopyrans; Carbamates; Cyclopropanes; Genotype; Hepacivirus; Hepatitis C, Chronic; Heterocyclic Compounds, 4 or More Rings; Humans; Lactams, Macrocyclic; Leucine; Proline; Quinoxalines; Sofosbuvir; Sulfonamides | 2022 |
A systematic exploration of boceprevir-based main protease inhibitors as SARS-CoV-2 antivirals.
Topics: Antiviral Agents; Carbamates; Carbutamide; COVID-19 Drug Treatment; Humans; Lactams; Leucine; Nitriles; Proline; Protease Inhibitors; SARS-CoV-2 | 2022 |